

9 Literaturverzeichnis

ABELSON, J.L.; Nesse, R.M.

Cholecystokinin-4 and panic.
Arch. Gen. Psychiatry 47: 395 (1990)

ABELSON, J.L.; Nesse, R.M.

Pentagastrin infusions in patients with panic disorder. 1. Symptoms and cardiovascular responses.
Biol. Psychiatry 36: 73 (1994)

ABELSON, J.L.; Nesse, R.M.; Vinik, A.I.

Pentagastrin infusions in patients with panic disorder. 2. Neuroendocrinology.
Biol. Psychiatry 36: 84 (1994c)

ADAMEC, R.E.; Sayin, U.; Brown, A.

The effects of corticotropin releasing factor (CRF) and handling stress on behavior in the elevated-plus-maze test of anxiety.
J. Psychopharmacol. 5 (3): 175-186 (1991)

ADAMEC, R.E.; Schallow, T.

Lasting effects on rodent anxiety of a single exposure to a cat.
Physiology and Behavior 54: 101-109 (1993)

AKAI, T.; Takahashi, M.; Nakada, Y.; Ohnishi, R.; Ikoma, Y.; Yamagushi, M.

Anxiolytic effects of lisuride and its agonistic action to central 5-HT_{1A} receptors.
Nippon Ykurigako Zasshi 97 (4): 209-220 (1991)

ALBONETTI, M.E.; Farabollini, F.

Behavioral responses to a single and repeated restraint in male and female rats.
Behav. Proc. 28: 97-110 (1992)

ALBUS, M.

Cholecystokinin.
Prog. Neuropsychopharmacol. Biol. Psychiatry 12: 5-21 (1988)

ALDER, T.; Morinan, A.

Strain differences in behavioral responses in murine models of anxiety.
Br. J. Pharmacol. 106: 45 (1992)

AMERICAN PSYCHIATRIC ASSOCIATION

DSM-IV: Diagnostic and Statistical Manual of Psychiatric Disorders, 4th Ed.
The American Psychiatric Association, Washington, DC. (1994)

ANDERSON, L.C.

Guinea pig husbandry and medicine.
Small Animal Practice 17 (5): 1045-1060 (1987)

ANDREWS, N.; File S.E.

Handling history modifies behavioural effects of drugs in the elevated-plus-maze test of anxiety.
Europ. J. Pharmacol. 235: 109-112 (1993)

ANDREWS, N.; File S.E.; Fernandes, C.; Gonzalez, L.E.; Barnes, N.M.

Evidence that the median raphe nucleus - dorsal hippocampal pathway mediates diazepam withdrawal-induced anxiety.
Psychopharmacology 130 (3): 228-234 (1997)

BALFOUR, D.J.K.; Graham, C.A.; Vale, A.L.

Studies on the possible role of brain 5-HT systems and adrenocortical activity in behavioral responses to nicotine and diazepam in an elevated-plus-maze.
Psychopharmacology 90: 528-532 (1986)

BANKS, W.A.

Evidence for a cholecystokinin gut-brain axis with modulation by bombesin.
Peptides 1: 347-351 (1980)

BANKS, W.A.; Kastin, A.J.

Passage of peptides across the blood-brain barrier: pathophysiological perspectives.
Life Sciences 59 (23): 1923-1943 (1996)

BARLOW, D.H.

Anxiety and its disorders.
Guilford Press, New York (1988)

BARRETT, R.W.; Steffey, M.E.; Wolfram, C.A.W.

Type-A cholecystokinin binding sites in cow brain: characterisation using (-)[³H]L364718 membrane binding assays.
Mol. Pharmacol. 36: 285-290 (1990)

BARRETT, J.E.; Vanover, K.

5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions.
Psychopharmacology 112: 1-12 (1993)

BARTFAI, T.; Iverfeldt, V.; Fisone, V.

Regulation of the release of co-existing neurotransmitters.
Ann. Rev. Pharmacol. Toxicol. 28: 285-310 (1988)

BARTH, T.; Rex, A.; Domeney, A.M.; Fink, H.

Effects of cholecystokinin fragments in three animal models of anxiety.
In: Gene - Brain - Behaviour. Elsner N., Heisenberg M. (Eds.); Stuttgart, New York, Georg Thieme Verlag 621 (1993)

BASSO, N.; Materia, A.; D'Intinosante, V.; Ginaldi, A.; Pona, V.; Reilly, P.; Ruggeri, S.; Fioravanti, M.

Effect of ceruletide on pituitary-hypothalamic peptides and on emotion in man.
Peptides 2 (2): 71 (1981)

BEAUFOR, C.; Ballon, N.; Le Bihan, C.; Hamon, M.; Thiébot, M.H.

Acute and chronic antidepressants: effects in conflict models of anxiety in rats.
Behav. Pharmacol. 8: 641 (1997)

BECKER, A.

The influence of diazepam on learning processes impaired by pentylenetetrazol kindling.
Naunyn Schmiedebergs Arch. Pharmacol. 349 (5): 492-496 (1994)

BENJAMIN, D.; Lal, H.; Meyerson, L.R.

The effects of 5-HT_{1B} characterizing agents in the mouse elevated-plus-maze.
Life Sci. 47: 195-203 (1990)

BERLYNE, D.E.

Conflict, arousal and curiosity.
McGraw-Hill, New York (1960)

BELZUNG, C.

State and trait anxiety? Common or different underlying mechanisms?
Abstract, XIIth Congress of the Polish Pharmacological Society (1995)

BELZUNG, C.; Pineau, N.; Beuzen, A.; Missslin, R.

PD135.158, a CCK_B antagonist reduces „state“ but not „trait“ anxiety.
Pharmacol. Biochem. Behav. 49: 433-436 (1994)

BELZUNG, C.; Lepape, G.

Comparison of different behavioral-test situations used in psychopharmacology for measurement of anxiety.
Physiol. Behav. 56: 623 (1994)

BEINFELD, M.C.

Inhibition of pro-cholecystokinin (CCK) sulfation by treatment with sodium chlorate alters its processing and decreases cellular content and secretion of CCK-8.
Neuropeptides 26 (3): 195-200 (1994)

- BEINFELD, M.C.; Meyer, D.K.; Brownstein, M.J.**
Cholecystokinin in the central nervous system.
Peptides 2 (2): 77-79 (1981)
- BEINFELD, M.C.; Ciarleglio, A.**
Neurochemistry of cholecystokinin in brain, pituitary and cerebrospinal fluid.
Ann. N.Y. Acad. Sci. 448: 44-52 (1985)
- BEINFELD, M.C.; Meyer, D.K.; Eskay, R.L.; Jensen, J.T.; Brownstein, M.J.**
The distribution of cholecystokinin-immunoreactivity in the central nervous system of the rat, as determined by radioimmunoassay.
Brain Res. 212: 51-57 (1981)
- BEINFELD, M.C.; Palkovits, M.**
Distribution of cholecystokinin (CCK) in the rat lower brain stem nuclei.
Brain Res. 238: 260-265 (1982)
- BERGMAN, J.; Paronis, C.A.**
Back to the future. Commentary on Rodgers, 'Animal models of anxiety: where next?'.
Behav. Pharmacol. 8: 502-504 (1997)
- BICKERDIKE, M.J.; Marsden, C.A.; Dourish, C.T.; Fletcher, A.**
The influence of 5-hydroxytryptamine reuptake blockade on CCK-receptor-antagonist effects in the rat elevated-zero-maze.
Eur. J. Pharmacol. 271: 403-411 (1995)
- BITRAN, D.; Hilvers, R.J.; Kellogg, C.K.**
Ovarian endocrine status modulates the anxiolytic potency of diazepam and the efficacy of gamma-aminobutyric acid-benzodiazepine receptor-mediated chloride ion transport.
Behav. Neurosci. 105: 653-662 (1991b)
- BLANCHARD, R.J.; Blanchard, D.C.; Agullana, R.; Weiss, S.M.**
Twenty-two kHz cries to presentation of a predator.
Physiology and Behavior 50: 967-972 (1991b)
- BLANKE, S.E.; Johnsen, A.H.; Rehfeld, J.F.**
N-terminal fragments of intestinal cholecystokinin - evidence for release of CCK-8 by cleavage on the carboxyl side of arg(74) of proCCK.
Regul. Pept. 46: 575-582 (1993)
- BODEN, P.; Hall, M.D.; Hughes, J.**
Cholecystokinin receptors.
Cellular and Molecular Neurobiology 15 (5): 545-559 (1995)
- BODEN, P.R.; Higginbottom, M.; Hill, D.R.; Horwell, D.C.; Hughes, J.; Rees, D.C.; Roberts, E.; Singh, L.; Suman-Chauhan, N.; Woodruff, G.N.**
Cholecystokinin dipeptoid antagonists: design, synthesis and anxiolytic profile of some novel CCK_A and CCK_B selective and "mixed" CCK_A/CCK_B antagonists.
J. Med. Chem. 36: 552-565 (1993)
- BODEN, P.R.; Woodruff, G.N.; Pinnock, R.D.**
Pharmacology of a cholecystokinin receptor on 5-hydroxytryptamine neurons in the dorsal raphe of the rat.
Br. J. Pharmacol. 102: 635-638 (1991)
- BODNOFF, S.R.; Suranyi-Cadotte, B.; Quirion, R.; Meaney, M.J.**
A comparison of the effects of diazepam versus several typical and atypical antidepressant drugs in an animal model of anxiety.
Psychopharmacology 97: 277-279 (1989)
- BOISSER, J.R.; Simon, P.; Soubrie, P.**
New approaches to the study of anxiety and anxiolytic drugs in animals.
In: Central Nervous System and Behavioral Pharmacology. Airaksinen M. (Ed.); Pergamon Press, Oxford: 213-222 (1976)

BOLLES, R.C.; Fanselow, M.S.

A perceptual-defensive-recuperative model of fear and pain.
Behav. Brain. Sci. 3: 291-302 (1980)

BOURIN, M.; Malinge, M.; Vasar, E.; Bradwejn, J.

Two faces of cholecystokinin: anxiety and schizophrenia.
Fundam. Clin. Pharmacol. 10: 116-126 (1996)

BOUTHILLIER, A.; DeMontigny, C.

Long-term benzodiazepine treatment reduces neuronal responsiveness to cholecystokinin: an electrophysiological study in the rat.
Eur. J. Pharmacol. 151: 135-138 (1988)

BRADLEY, P.B.; Engel, G.; Feniuk, W.; Fozard, J.R.; Humphrey, P.P.A.; Middlemiss, D.N.; Myle-Charane, E.J.; Richardson, B.P.; Saxena, P.R.

Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine.
Neuropharmacology 25: 563-576 (1986)

BRADWEJN, J.

Cholecystokinin and panic disorders.

In: *Cholecystokinin and Anxiety: from Neuron to Behavior*. Bradwejn J., Vasar E. (Eds.); Austin RD Landes Comp.: 73-86 (1995)

BRADWEJN, J.; Koszycki, D.

Imipramine antagonism of the panicogenic effects of cholecystokinin-tetrapeptide in panic disorder patients.

Am. J. Psychiatry 151: 261-363 (1994)

BRADWEJN, J.; Koszycki, D.; Couetoux du Tertre, A.; Bourin, M.; Palmour, R.; Ervin, F.

The cholecystokinin hypothesis of panic and anxiety disorders: a review.
J. Psychopharmacol. 6: 345-351 (1992)

BRADWEJN, J.; Koszycki, D.; Couetoux du Tertre, A.; VanMegen, H.; denBoer, J.; Westenberg, H.; Annable, L.

The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L365.260, a central cholecystokinin receptor antagonist, in patients with panic disorder.

Arch. Gen. Psychiatry 51: 486-493 (1994)

BRADWEJN, J.; Koszycki, D.; Meterissian, G.

Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder.

Can. J. Psychiatry 35 (1): 83-85 (1990)

BRADWEJN, J.; Koszycki, D.; Shriqui, C.

Enhanced sensitivity to cholecystokinin-tetrapeptide in panic disorder.

Arch. Gen. Psychiatry 48: 603-610 (1991)

BRADWEJN, J.; DeMontigny, C.

Benzodiazepines antagonise cholecystokinin-induced activation of rat hippocampal neurons.

Nature 312: 363-364 (1984)

BRAMBILLA, F.; Bellodi, L.; Perna, G.; Garberi, A.; Sacerdote, P.

Lymphocyte cholecystokinin concentrations in panic disorder.

Am. J. Psychiatry 150: 1111-1113 (1993)

BRETT, R.R.; Pratt, J.A.

Chronic handling modifies the anxiolytic effect of diazepam in the elevated-plus-maze.

Eur. J. Pharmacol. 178: 135-138 (1990)

BRILEY, M.; Filion, G.

Pasteur euroconference on future therapies for an anxious world.

Expert Opin. Invest. Drugs 7 (1): 113-116 (1998)

BRITTON, D.R.; Britton, K.T.

A sensitive open-field measure of anxiolytic drug sensitivity.

Pharmacol. Biochem. Behav. 15: 577-582 (1981)

BRITTON, K.T.; Page, M.; Baldwin, H.A.; Koob, G.F.

Anxiolytic activity of steroid anaesthetic alphaxalone.

J. Pharmacol. Exp. Ther. 258: 124-129 (1991)

BROADHURST, P.L.

Experiments in psychogenetics.

In: Experiments in Personality, Psychogenetics and Psychopharmacology. Eysenck H.J. (Ed.);

Routledge und Kegan Paul, London 1: 3-102 (1960a)

BRODIE, M.S.; Dunwiddie, T.V.

Cholecystokinin potentiates dopamine inhibition of mesencephalic dopamine neurons in vitro.

Brain Res. 425: 106-113 (1987)

BUCHAN, A.M.; Polak, J.M.; Solcia, E.; Cappella, C.; Hudson, D.; Pearse, G.E.

Electron immunohistochemical evidence for the human intestinal I-cell as source of CCK.

Gut 19: 403-407 (1978)

BURES, J.; Buresova, O.; Huston, J.

Techniques and basic experiments for the study of brain and behaviour. 2nd Ed.

Elsevier Science Publishers B.V., Amsterdam, Netherlands (1983)

CAMPBELL, J.L.; Sherman, A.D.; Petty, F.

Diazepam anxiolytic activity in hippocampus.

Commun. Psychopharmacol. 4: 387 (1980)

CHANG, R.S.L.; Chen, T.B.; Bock, M.; Freidinger, R.M.; Chen, R.; Rosegay, A.; Lotti, V.J.

Characterisation of the binding of (³H)L365.260: a new potent and selective brain Cholecystokinin (CCK_B) and gastrin receptor antagonist radioligand.

J. Pharmacol. Exp. Ther. 35: 803-808 (1989)

CHANG, R.S.L.; Lotti, V.J.; Chen, T.B.

Characterisation of (³H)-(+/-)-L364.718 binding to solubilized Cholecystokinin (CCK) receptors of rat pancreas.

Biochem. Pharmacol. 36 (10): 1709-1714 (1987)

CHANG, R.S.L.; Lotti, V.J.; Chen, T.B.; Kunkel, K.A.

Characterisation of the binding of (³H)-(+/-)-L364.718: a new potent, nonpeptide Cholecystokinin antagonist radioligand selective for peripheral receptors.

Mol. Pharmacol. 30 (3): 212-217 (1986)

CHANG, R.S.L.; Lotti, V.J.

Biochemical and pharmacological characterisation of extremely potent and selective nonpeptide cholecystokinin antagonist.

Proc. Natl. Acad. Sci. USA 83: 4923-4926 (1986)

CHANG, R.S.L.; Lotti, V.J.; Monaghan, R.L.; Birnbaum, J.; Stapley, E.O.; Goetz, M.A.;

Albers-Schonberg, G.; Patchett, A.A.; Liesch, J.M.; Hensens, O.D.; Springer, J.P.

A potent nonpeptide cholecystokinin-antagonist selective for peripheral tissues isolated from *Aspergillus alliaceus*.

Science 230: 177-179 (1985)

CHAOULOFF, F.; Kulikov, A.; Sarrieau, A.; Castanon, N.; Mormède, P.

Male Fischer 344 and Lewis rats display differences in locomotor reactivity, but not in anxiety-related behaviours: relationship with the hippocampal serotonergic system.

Brain Research 693: 169-178 (1995)

CHARNEY, D.S.; Woods, S.W.; Goodman, W.K.; Heninger, G.R.

Serotonin function in anxiety. II. Effects of the serotonin agonist mCPP on panic disorder patients and healthy subjects.

Psychopharmacology 92: 14-21 (1987)

CHOPIN, P.; Briley, M.

The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated-plus-maze.

Psychopharmacology (Berlin) 110: 409-414 (1993)

CHOPIN, P.; Briley, M.

Animal models of anxiety: the effect of compounds that modify 5-HT neurotransmission.
TIPS 8: 383-388 (1987)

CHRISTMAS, A.J.; Maxwell, D.R.

A comparison of the effects of some benzodiazepines and other drugs on aggressive and exploratory behaviour in mice and rats.
Neuropharmacology 9: 17-29 (1970)

COHEN, S.L.; Crouse, M.S.

Failure to find antianxiety properties of cholecystokinin-octapeptide.
Bull. Psycho. Soc. 25: 204 (1987)

COLLINS, S.; Walker, D.; Forsyth, P.; Belbeck, L.

The effects of proglumide on cholecystokinin-, bombesin-, and glucagon-induced satiety in the rat.
Life Sci. 32: 2223-2229 (1983)

COMMISARIS, R.L.; Harrington, G.M.; Altmann, H.J.

Benzodiazepine anti-conflict effects in Maudsley reactive (MR/Har) and non-reactive (NMR/Har) rats.
Psychopharmacology 100: 287-292 (1990)

COOPER, S.J.

Benzodiazepines as appetite-enhancing compounds.
Appetite 1: 7-19 (1980)

CORP, E.S.; McQuade, J.; Moran, T.H.; Smith, G.P.

Characterisation of type A and B CCK receptor binding sites in rat vagus nerve.
Brain Res. 623: 161-166 (1993)

COSTALL, B.; Kelly, M.E.; Tomkins, D.M.

Use of the elevated-plus-maze to assess anxiolytic potential in the rat.
Br. J. Pharmacol. 96: 312 (1989a)

COSTALL, B.; Naylor, R.J.

Anxiolytic potential of 5-HT₃ receptor antagonists.
Pharmacol. Toxicol. 70: 157 (1992)

COSTALL, B.; Domeney, A.M.; Hughes, J.; Kelly, M.E.; Naylor, R.J.; Woodruff, G.N.

Anxiolytic effects of CCK_B antagonists.
Neuropeptides 19 (Suppl.): 65-73 (1991)

COSTALL, B.; Domeney, A.M.; Gerrard, P.A.; Kelly, M.E.; Naylor, R.J.

Zacopride: anxiolytic profile in rodent and primate models of anxiety.
J. Pharm. Pharmacol. 40: 302-305 (1988)

COX, J.E.; Randich, A.

CCK-8 activates hepatic vagal C-fibre afferents.
Brain Res. 776 (1-2): 189-194 (1997)

CRAWLEY, J.N.

Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway.
J. Neurosci. 12: 3380-3391 (1992)

CRAWLEY, J.N.

Neuropharmacological specificity of a simple animal model for the behavioral actions of benzodiazepines.
Pharmacol. Biochem. Behav. 15: 695-699 (1981)

CRAWLEY, J.N.

Comparative distribution of cholecystokinin and other neuropeptides - why is this peptide different from all other peptides.
Ann. N.Y. Acad. Sci. 448: 1-8 (1985)

CRAWLEY, J.N.

Cholecystokinin-dopamine interactions.
TIPS 12: 232-236 (1991)

- CRAWLEY, J.N.; Corwin, R.L.**
Biological actions of cholecystokinin.
Peptides 15: 731-755 (1994)
- CRAWLEY, J.N.; Goodwin, F.K.**
Preliminary report of a simple animal behaviour model for the anxiolytic effects of benzodiazepines.
Pharmacol. Biochem. Behav. 13: 167-170 (1980)
- CRUZ, A.P.M.; Frei, F.; Graeff, F.G.**
Ethopharmacological analysis of rat behaviour on the elevated-plus-maze.
Pharmacol. Biochem. Behav. 49: 171 (1994)
- CSONKA, E.; Fekete, M.; Nagy, G.; Szanto-Fekete, M.; Feledyg, G.; Penke, P.; Kovacs, K.**
Anxiogenic effect of cholecystokinin in rats.
In: Peptides. Walter deGruter & Co., New York 249 (1988)
- CURZON, G.; Kennett, G.A.**
MCPD a tool for studying behavioral responses associated with 5-HT_{1C} receptors.
Trends Pharmacol. Sci. 11: 181-182 (1990)
- CUTLER, N.R.; Sramek, J.J.; Kramer, M.S.; Reines, S.A.**
Placebo-controlled study of a CCK_B antagonist in patients with panic disorder.
Biol. Psychiatry 35: 680 (1994)
- DaCUNHA, C.; Levi de Stein, M.; Wolfman, C.**
Effects of various training procedures on performance in an elevated-plus-maze: possible relation with brain regional levels of benzodiazepine-like molecules.
Pharmacol. Biochem. Behav. 43: 677-681 (1992)
- DAHL, D.**
Systemically administered cholecystokinin affects an evoked potential in the hippocampal dentate gyrus.
Neuropeptides 10: 165-173 (1987)
- DALSGAARD, C.-J.; Vincent, S.R.; Hökfelt, T.; Lundberg, M.; Dahlstrom, A.; Schultzberg, M.; Dockray, G.J.; Cuello, C.**
Coexistence of cholecystokinin and substance-P like peptides in neurons of the dorsal root ganglia of the rat.
Neurosci. Lett. 33: 159-163 (1982)
- DAUGE, V.; Corringer, P.-J.; Roques, B.P.**
CCK_A, but not CCK_B, agonists suppress the hyperlocomotion induced by endogenous enkephalins, protected from enzymatic degradation by systemic RB101.
Pharmacol. Biochem. Behav. 50: 133 (1995)
- DAVISON, J.S.; Najafi-Farashah, A.**
Dibutryl-cyclic-GMP, a competitive inhibitor of cholecystokinin/pancreozymin and related peptides in the gall bladder and ileum.
Can. J. Physiol. Pharmacol. 59: 1100-1104 (1981)
- DAWSON, G.R.; Rupniak, N.M.J.; Iversen, S.D.; Tricklebank, M.D.**
Lack of CCK_B receptor antagonists in animal screens for anxiolytic drugs.
J. Psychopharmacol. 8: A47 (1994)
- DEAKIN, J.F.W.; Graeff, F.G.**
5-HT mechanisms and mechanisms of defence.
Jour. Psychopharmacol. 5: 305-315 (1991)
- DELLA-FERA, M.A.; Baille, C.A.**
Cholecystokinin-octapeptide: continuous picomole injections into the cerebral ventricles of sheep suppress feeding.
Science 206: 471 (1979)
- DeMONTIGNY, C.**
Cholecystokinin-tetrapeptide induces panic-like attacks in healthy volunteers.
Arch. Gen. Psychiatry 46: 511-517 (1989)

DENENBERG, V.H.

Open-field behaviour in the rat: what does it mean?

Ann. N.Y. Acad. Sci. 159: 852-859 (1969)

DENYER, J.; Gray, J.; Wong, M.; Stolz, M.; Tate, S.

Molecular and pharmacological characterisation of the human CCK_B receptor.

Eur. J. Pharmacol. 268: 29-41 (1994)

DERRIEN, M.; McCort-Tranchepain, I.; Ducos, B.; Roques, B.P.; Durieux, C.

Heterogeneity of CCK_B receptors involved in animal-models of anxiety.

Pharmacol. Biochem. Behav. 49: 133 (1994)

DESCHENS, R.J.; Lorenz, L.J.; Haun, R.S.; Roos, B.A.; Collier, K.J.; Dixon, J.E.

Cloning and sequence analysis of a cDNA encoding rat prepro-cholecystokinin.

Proc. Natl. Acad. Sci. USA 81: 726-730 (1984)

DESCHODT-LANCKMAN, M.

Characterisation of membrane-bound CCK-8-degrading enzymes from rat brain.

Arch. Int. Physiol. Biochem. 90: B107-B108 (1982)

DESCHODT-LANCKMAN, M.; Koulischer, D.; Przedborski, S.; Lauwereys, M.

Cholecystokinin octa- and tetrapeptide degradation by synaptic membranes. III. Inactivation of CCK-8 by a phosphoramidon-sensitive endopeptidase.

Peptides 5 (3): 649-651 (1984)

DEUPREE, D.; Hsiao, S.

Cholecystokinin-octapeptide, proglumide and conditioned taste avoidance in rats.

Peptides 8: 25-28 (1987)

DEUPREE, D.; Hsiao, S.

Cholecystokinin-octapeptide increases passive avoidance latencies in rats.

Physiol. Behav. 42: 203-205 (1988)

DEZUBE, M.; Sugg, E.E.; Birkemo, L.S.; Croom, D.K.; Dogherty, R.W. jr.; Ervin, G.N.; Grizzle, M.K.; James, M.K.; Johnson, M.F.; Mosher, J.T.; Queen, K.L.; Rimele, T.J.; Sauls, H.R. jr.; Triantafillou, J.A.

Modification of receptor selectivity and functional activity of cholecystokinin-peptoid ligands.

Jour. Med. Chem. 38 (17): 3384-3390 (1995)

DIMALINE, R.; Lee, C.M.

Biological properties of chicken gastrin: a member of the gastrin/CCK family with novel structure-activity relationships.

Physiol. 259: 9882-9888 (1990)

DOCKRAY, G.J.

Immunohistochemical evidence of cholecystokinin-like peptides in brain.

Nature (Lond.) 264: 568-570 (1976)

DOCKRAY, G.J.

CCK neurones and receptors in the CNS.

Introduction in: Multiple Cholecystokinin Receptors in the CNS. Dourish C.T., Cooper S.J., Iversen S.D., Iversen L.L. (Eds.); Oxford University Press, Oxford 3 (1992)

DOCKRAY, G.J., Gregory, R.A., Hutchison, J.B., Harris, J.I., Runswick, M.J.

Isolation, structure and biological activity of two cholecystokinin-octapeptides from sheep brain.

Nature 274: 711-713 (1978)

DOCKRAY, G.J.; Gregory, R.A.; Tracy, H.J.; Zhu, W.Y.

Transport of cholecystokinin-octapeptide like immunoreactivity toward the gut in afferent vagal fibres in cat and dog.

J. Physiol. Lond. 314: 501-511 (1981)

DOCKRAY, G.J.; Johnsson, A.C.; Desmond, H.; Varro, A.

1. Int. Conference on Neuronal CCK.

Abstract 3, Brüssel (1984)

DOCKRAY, G.J.; Vaillant, C.; Hutchison, J.B.

Immunochemical characterisation of peptides in endocrine cells and nerves with particular reference to gastrin and cholecystokinin.

In: Cellular basis of chemical messengers in the digestive system. Grossman M.I., Brazier M.A.B., Lechago J. (Eds.); New York, Academic Press: 215-230 (1981)

DODD, P.R.; Edwardson, J.A.; Dockray, G.J.

The depolarisation-induced release of cholecystokinin C-terminal octapeptide (CCK-8) from rat synaptosomes and brain slices.

Regul. Peptides. 1: 17-29 (1980)

DODD, J.; Kelly, J.S.

The actions of cholecystokinin and related peptides on pyramidal neurones of the mammalian hippocampus.

Brain Research 205: 337-350 (1981)

DOMPERT, W.U.; Glaser, T.; Traber, J.

3H-TVXQ 7821: identification of 5-HT binding sites as target for a novel putative anxiolytic.

Naunyn Schmiedebergs Arch. Pharmacol. 328: 467-470 (1985)

DOOLEY, D.J.; Klamt, I.

Differential profile of the CCK_B receptor antagonist CI-988 and diazepam in the 4-plate test.

Psychopharmacology 112: 452-454 (1993)

DOURISH, C.T.; Hill, D.R.

Classification and function of CCK receptors.

Trends. Pharmacol. Sci. 8: 207-208 (1987)

DOURISH, C.T.; Bickerdike, M.J.; Stanhope, K.J.; Fletcher, A.; Marsden, C.A.

Profile of CCK_A and CCK_B receptor antagonists in the CER and elevated zero-maze models of anxiety in the rat: modulation by 5-HT reuptake blockade.

Behav. Pharmacol. 5 (1): 29-30 (1994)

DOURISH, C.T.; Rycroft, W.; Dawson, G.R.; Tattersall, F.D.; Iversen, S.D.

Anxiolytic effects of the CCK antagonists devazepide and L365.260 in a conditioned suppression of drinking model.

Eur. J. Neurosci. 2: 38 (1990)

DRAWER, K.; Ennulat, K.J. (Hrsg.)

Tierschutzgerechtes Töten von Wirbeltieren.

Tierschutzpraxis; Gustav Fischer Verlag Stuttgart, New York: 293-300 (1977)

DUBROEUCQ, M.C.; Guyon, C.; Manfré, F.; Capet, M.; Barreau, M.; Bertrand, P.; Jean-tard, B.; Doble, A.; Blanchard, J.-C.

Evaluation of brain penetration of CCK_B antagonists.

Ann. N.Y. Acad. Sci. 713: 377-379 (1994)

DUNN, R.W.; Corbett, R.; Fielding, S.

Effects of 5-HT_{1A} receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze.

Eur. J. Pharmacol. 169: 1-10 (1989)

EBERLEIN, G.A.; Eysselein, V.E.; Goebel, H.

Cholecystokinin-58 is the major molecular form in man, dog and cat but not in pig, beef and rat intestine.

Peptides 9: 993-998 (1988)

EDWARDS, J.G.

Clinical anxiety and its treatment.

Neuropeptides 19 (Suppl.): 1-10 (1991)

ELLINWOOD, E.H.; Rockwell, W.; Wagoner, N.

Apomorphine behavioral effect is mediated by dibutryl/cAMP and inhibited by cearulein.

Psychopharm. Bull. 19: 352-354 (1983)

EMMANOUIL, D.E.; Quock, R.M.

Effects of benzodiazepine agonist, inverse agonist and antagonist drugs in the mouse staircase test.
Psychopharmacology 102: 95-97 (1990)

EMSON, P.C.; Hunt, S.; Rehfeld, J.F.; Goterman, N.; Fahrenkrug, J.

Cholecystokinin and vasoactive intestinal polypeptide in the mammalian CNS: distribution and possible physiological roles.

In: *Neural peptides and neuronal communication*. Costa E., Trabucchi M. (Eds.); New York: Raven Press (1980)

ENG, J.; Shiina, Y.; Pan, Y.-C.E.; Blacher, R.; Chang, M.; Stein, S.; Yalow, R.S.

Pig brain contains cholecystokinin-octapeptide and several cholecystokinin-desoctapeptides.

Proc. Natl. Acad. Sci. USA 80: 6381-6385 (1983)

ENGELMAN, K.; Lovenberg, W.; Sjoerdsma, A.

Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome.

N. Engl. J. Med. 277 (21): 1103-1108 (1967)

EVANS, B.E.; Rittle, K.E.; Bock, M.G.; DiPardo, R.M.; Freidinger, R.F.; Whitter, W.L.;

Lundel, G.F.; Veber, D.F.; Anderson, P.S.; Chang, R.S.L.; Lotti, V.J.; Cerino, D.J.;

Chen, T.B.; Kling, P.J.; Kunkel, K.A.; Springer, P.J.; Hirschfeld, J.

Methods for drug discovery: development of potent, selective, orally effective cholecystokinin-antagonists.

J. Med. Chem. 31: 2235-2246 (1988)

EVANS, B.E.; Bock, M.G.; Rittle, K.E.; Dipardo, R.M.; Whitter, W.L.; Veber, D.F.; Anderson, P.S.; Freidinger, R.M.

Design of potent, oral effective nonpeptidal antagonists of the peptide hormone cholecystokinin.

Proc. Natl. Acad. Sci. USA 83: 4918 (1986)

EYSENCK, M.W.

Cognitive factors in clinical anxiety, potential relevance to therapy.

In: *New Concepts in Anxiety*. Briley M., File S.E. (Eds.); McMillan, London: 418 (1989)

EYSSELEIN, V.E.; Botcher, W.; Kauffman, G.L.; Walsh, J.H.

Molecular heterogeneity of canine cholecystokinin in portal and peripheral plasma.

Regul. Pept. 9: 173-185 (1984)

FALLON, J.H.; Seroogy, K.B.

The distribution and some connections of the cholecystokinin neurones in rat brain.

Ann. N.Y. Acad. Sci. 448: 121-132 (1985)

FALTER, U.; Gower, A.J.; Gobert, J.

Resistance of baseline activity in the elevated-plus-maze to exogenous influences.

Behavioral Pharmacology 3: 123-128 (1992)

FAN, Z.W.; Eng, J.; Miedel, M.; Hulmes, J.D.; Pan, Y.-C. E.; Yalow, R.S.

Cholecystokinin-octapeptides purified from chinchilla and chicken brains.

Brain Res. Bull. 18: 757-760 (1987)

FARABOLLINI, F.; File, S.E.; Johnston, A.L.; Wilson, C.A.

An analysis of sex differences in the open-field and tests of exploration anxiety.

Br. J. Pharmacol. 90: 263 (1987)

FEKETE, M.; Lengyel, A.; Hegedus, B.; Penke, P.; Zarandy, M.; Toth, G.K.; Telegdy, G.

Further analysis of the effects of cholecystokinin-octapeptides on avoidance-behaviour in rats.

Eur. J. Pharmacol. 98: 79 (1984)

FILE, S.E.

Animal models for predicting clinical efficacy of anxiolytic drugs: social behaviour.

Neuropsychobiology 13: 55-62 (1985b)

FILE, S.E.

One-trial tolerance to the anxiolytic effects of chlordiazepoxide in the plus-maze.

Psychopharmacology 100: 281-282 (1990a)

FILE, S.E.

Age and anxiety: increased anxiety, decreased anxiolytic but enhanced sedative response to chlordiazepoxide in old rats.

Hum. Psychopharmacol. 5: 169-173 (1990b)

FILE, S.E.

Behavioral detection of anxiolytic action.

In: *Experimental Approaches to Anxiety and Depression*. Elliot J.H., Heal D.J., Marsden, C.A. (Eds.); Wiley, Chichester, Chapter III: 25-44 (1992)

FILE, S.E.; Day, S.

Effects of time of day and food deprivation on exploratory activity in the rat.

Anim. Behav. 20: 758-762 (1972)

FILE, S.E.; Pellow, S.

No cross-tolerance between the stimulatory and depressant actions of benzodiazepines in mice.

Behav. Brain Res. 17: 1-7 (1985)

FILE, S.E.; Andrews, N.; Wu, P.Y.; Zangrossi, H.jr.

Modification of chlordiazepoxide's behavioral and neurochemical effects by handling and plus-maze experience.

Eur. J. Pharmacol. 218: 9-14 (1992)

FINK, F.; Erdmann, H.; Fink, H.; Morgenstern, R.

WP A61B/225 736, Pat.-Schr.Nr. 155033

DDR

FINK, H.; Morgenstern, R.; Oelsner, W.

Clozapine - A serotonin antagonist?

Pharmacol. Biochem. Behav. 20: 513-517 (1984)

FINK, H.; Rex, A.; Morgenstern, R.

Behavioral and neurochemical effects of CCK-fragments in animal models of anxiety.

Behav. Pharmacol. 5: 30 (1994)

FINK, H.; Rex, A.; Voits, M.; Voigt, J.P.

Major biological actions of CCK.

Experimental Brain Research 117 (Suppl.): 9 (1997)

FORTH, W.; Henschler, D.; Rummel, W.

Allgemeine und spezielle Pharmakologie und Toxikologie 5. Aufl..

Bibliographisches Institut & F.A. Brockhaus AG (1987)

FREEMAN, A.S.; Bunney, B.S.

Activity of A9 and A10 dopaminergic neurons in unrestrained rats: Further characterisation and effects of apomorphine and cholecystokinin.

Brain Res. 405: 46-55 (1987)

FREIDINGER, R.M.

Cholecystokinin and gastrin antagonists.

Med. Res. Rev. 9 (3): 271 (1989)

FREIDINGER, R.M.

Toward peptide receptor ligand drugs: progress on neuropeptides.

In: *Progress in Drug Research*. Jucker W.R. (Ed.); Birkhauser Verlag, Basel: 33 (1993)

FREUD, S.

Über Coca.

In: *Centralblatt für die gesamte Therapie*. Wien (Perles), 2: 289-314 (1884)

FREY, P.

Cholecystokinin-octapeptide levels in rat brain after subchronic neuroleptic treatment.

Eur. J. Pharmacol. 95 (1-2): 87-92 (1983)

FRIEDMAN, N.; Landesman, H.M.; Wexler, M.

The influences of fear, anxiety, and depression on the patient's adaptive responses to complete dentures. Part I.

J. Prosthet. Dent. 58: 687-689 (1987)

FRUSSA-FILHO, R.; Otoboni, J.R.; Gianotti, A.D.

Effect of age on antinociceptive effects of elevated-plus-maze exposure.
Brazilian J. Med. Biol. Res. 25: 827-829 (1992)

GALL, C.; Lauterborn, J.; Burks, D.; Seroogy, K.

Co-localisation of enkephalin and cholecystokinin in discrete areas of rat-brain.
Brain Res. 403: 403 (1987)

GARDNER, C.R.

Distress vocalisation in rat pups: a simple screening method for anxiolytic drugs.
Journal of Pharmacological Methods 14: 181-187 (1985)

GAUDREAU, P.; Quiron, R.; St-Pierre, S.; Pert, C.B.

Characterisation and visualisation of cholecystokinin receptors in rat brain using [³H] pentagastrin.
Peptides 4: 755-762 (1983)

GEORGE, M.S.; Guidotti, A.; Rubinow, D.; Pan, B.S.; Mikalaukas, K.; Post, R.M.

CSF neuroaktive steroids in affective-disorders - pregnenolone, progesterone und DBI.
Biol. Psychiatry 35: 775 (1994)

GERHARDT, P.; Voits, M.; Fink, H.; Huston, J.P.

Evidence for mnemotropic action of cholecystokinin fragments Boc-CCK-4 and CCK-8S.
Peptides 15 (4): 689-697 (1994)

GLASER, T.; Traber, J.

Binding of the putative anxiolytic TVX Q 7821 to hippocampal 5-hydroxytryptamine (5-HT) recognition sites.
Naunyn Schmiedebergs Arch. Pharmacol. 329: 211-215 (1985)

GOA, K.L.; Ward, A.

Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic.
Drugs 32: 114-129 (1986)

GOLDMAN, S.; Pelaprat, D.; Van Reeth, O.; Roques, B.P.; Vanderhaeghen, J.-J.

Autoradiographic localisation of the cholecystokinin binding sites in human cerebellar system using a [¹²⁵I]CCK-8 probe.
Neurochem. Int. 10 (4): 467-471 (1987)

GOLTERMANN, N.R.; Stengaard Pedersen, K.; Rehfeld, J.F.; Christensen, N.J.

Newly synthesised cholecystokinin in subcellular fractions of the rat brain.
J. Neurochem. 36: 959-965 (1981)

GOLTERMANN, N.R.; Rehfeld, J.F.; Roigaard-Petersen, H.

In vivo biosynthesis of cholecystokinin in the rat cerebral cortex.
J. Biol. Chem. 255: 6181-6185 (1980)

GOOD, B.J.; Kleinman, A.M.

Culture and anxiety: cross-cultural evidence for the patterning of anxiety disorders.
In: Anxiety and Anxiety Disorders. Tuma A.H., Maser J.D. (Eds.); Erlbaum, Hillsdale, NJ: 297-323 (1985)

GRAEF, F.G.; Schoenfeld, R.I.

Tryptamine mechanism in punished and nonpunished behavior.
J. Pharmacol. Exp. Ther. 173: 277-283 (1970)

GRAEF, F.G.

Brain defence systems and anxiety.
In: Handbook of Anxiety: The Neurobiology of Anxiety. Burrows G., Roth M., Noyes, C. (Eds.); Amsterdam Elsevier: 307-354 (1990)

GRAY, J.A.

Emotionality in male and female rodents: a reply to Archer.
Br. J. Psychol. 70: 425-440 (1979)

GRAY, J.A.

The neuropsychology of anxiety: an inquiry into the functions of the septo-hippocampal system.
OUP, New York (1982)

GREEN, S.; Hodges, H.

Animal models of anxiety.

In: Behavioral Models in Psychopharmacology. Willner P. (Ed.); Cambridge University Press 21 (1991)

GREEN, S.; Vale, H.

Role of amygdaloid nuclei in the anxiolytic effects of benzodiazepines in rats.

Behav. Pharmacol. 3: 261-264 (1992)

GRIEBEL, G.

5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research.

Pharmac. Ther. 65: 319-395 (1995)

GRIEBEL, G.; Blanchard, D.C.; Blanchard, R.J.

Evidence that the behaviours in the mouse defense test battery relate to different emotional states: a factor analytic study.

Physiology and Behaviour 60: 1255-1260 (1996a)

GRIEBEL, G.; Blanchard, D.C.; Blanchard, R.J.

Predator-elicited flight responses in Swiss Webster mice: an experimental model of panic attacks.

Progress in Neuro-Psychopharmacology and Biological Psychiatry 20: 185-205 (1996b)

GRIEBEL, G.; Moreau, J.L.; Jenck, F.; Martin, J.R.; Misslin, R.

Some critical determinants of the behavior of rats in the elevated-plus-maze.

Behavioral Processes 29: 37-48 (1993)

GRIEBEL, G.; Perrault, Gh.; Sanger, D.J.

CCK receptor antagonists in animal models of anxiety: comparison between exploration tests, conflict procedures and a model based on defensive behaviour.

Behav. Pharmacol. 8: 549-560 (1997)

GRIEBEL, G.; Sanger, D.J.; Perrault, Gh.

Genetic differences in the mouse defense test battery.

Aggressive Behaviour 23: 19-31 (1997)

GRIMMELIKHUIJZEN, C.J.P.; Sundler, F.; Rehfeld, J.F.

Gastrin/CCK immunoreactivity in the central nervous system of coelenterates.

Histochemistry 69: 61-68 (1980)

GUIMARAES, F.S.; Chiaretti, T.M.; Graeff, F.G.; Zuardi, A.W.

Antianxiety effect of cannabidiol in the elevated-plus-maze.

Psychopharmacology 100: 558-559 (1990)

HALL, C.S.

Emotional behaviour in the rat. I. Defecation and urination as measures of individual differences in emotionality.

J. Compr. Psychol. 18: 385-403 (1934)

HALL, C.S.

The inheritance of emotionality.

Sigma Xi Q 26: 17-27 (1938)

HAMILTON, M.

The assessment of anxiety states by rating.

Br. J. Med. Psych. 32: 50 (1959)

HANDLEY, S.

Future prospects for the pharmacological treatment of anxiety.

CNS Drugs 2: 397 (1994)

HANDLEY, S.L.

Serotonin in animal models of anxiety: the importance of stimulus and response.

In: Serotonin, Sleep and Mental Disorder. Idzikovski C., Cohen P.J. (Eds.); Wrihston, London: 89-115 (1991)

- HANDLEY, S.L.; McBlane, J.W.**
5-HT drugs in animal models of anxiety.
Psychopharmacology 112: 13-20 (1993)
- HANDLEY, S.L.; McBlane, J.W.; McCreary, A.C.**
Serotonin and anxiety - multiple mechanisms in the elevated-plus-maze.
Pol. Pharmacol. 47 (Suppl.): 16 (1995)
- HANDLEY, S.L.; Mithani, S.**
Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of "fear"-motivated behaviour.
Naunyn Schmiedebergs Arch. Pharmacol. 327: 1-5 (1984)
- HARPER, A.A.; Raper, H.S.**
Pancreozymin, a stimulant of the secretion of pancreatic enzymes in extracts of the small intestine.
J. Physiol. 102: 115-125 (1943)
- HARPER, E.A.; Roberts, S.P.; Shankley, N.P.; Black, J.W.**
Analysis of variation in L365.260 competition curves in radioligand binding assays.
Brit. Jour. Pharmacol. 118: 1717-1726 (1996)
- HARRO, J.; Kiivet, R.-A.; Lang, A.; Vasar, E.**
Rats with anxious or non-anxious type of exploratory behaviour differ in their brain CCK-8 and benzodiazepine receptor characteristics.
Behav. Brain Res. 39: 63-71 (1990a)
- HARRO, J.; Lang, A.; Vasar, E.**
Long-term Diazepam treatment produces changes in cholecystokinin receptor-binding in rat brain.
Eur. J. Pharmacol. 180: 77 (1990)
- HARRO, J.; Orelund, L.; Vasar, E.**
Cholecystokinin receptors and animal models of anxiety.
Clin. Neuropharmacol. 15 (Suppl. 1): 479A-480A (1992)
- HARRO, J.; Pold, M.; Vasar, E.**
Anxiogenic-like action of ceruletide, a CCK-8 receptor antagonist, in the mouse: influence of acute and subchronic diazepam treatment.
Naunyn Schmiedebergs Arch. Pharmacol. 341: 62-67 (1990b)
- HARRO, J.; Vasar, E.**
Evidence that CCK-B receptors mediate the regulation of exploratory behaviour in the rat.
Eur. J. Pharmacol. 193: 379-381 (1991)
- HARRO, J.; Vasar, E.**
Cholecystokinin-induced anxiety - how is it reflected in studies on exploratory behaviour?
Neurosci. Biobehav. Rev. 15: 473 (1991a)
- HARRO, J.; Vasar, E.; Bradwejn, J.**
CCK in animal and human research on anxiety.
Trends. Pharmacol. Sci. 14: 244-249 (1993)
- HAYS, S.E.; Beinfeld, M.C.; Jensen, R.T.; Goodwin, F.K.; Paul, S.M.**
Demonstration of a putative receptor site for cholecystokinin in rat brain.
Neuropeptides 1: 53-62 (1980)
- HEILIG, M.; McLeod, S.; Brot, M.; Heinrichs, S.C.; Menzaghi, F.; Koob, G.F.; Britton, K.T.**
Anxiolytic-like action of neuropeptid Y - mediation by Y₁ receptors in amygdala, and dissociation from food-intake effects.
Neuropsychopharmacology 8: 357 (1993)
- HEINRICHS, S.C.; Menzaghi, F.; Pich, E.M.; Baldwin, H.A.; Rassnik, S.; Britton, K.T.; Koob, G.F.**
Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity.
Neuropsychopharmacology 11: 179 (1994)

HEINRICHS, S.C.; Pich, E.M.; Micek, K.A.; Britton, K.T.; Koob, G.F.

Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotrophic action.

Brain Res. 581: 190-197 (1992)

HENDRIE, C.A.; Neill, J.C.

Ethological analysis of the role of CCK in anxiety.

In: *Multiple Cholecystokinin Receptors in the CNS*. Dourish C.T., Cooper S.J., Iversen S.D., Iversen L.L. (Eds.); Oxford University Press, Oxford: 132 (1992)

HENDRIE, C.A.; Neill, J.C.; Shepherd, J.K.; Dourish, C.T.

The effects of CCK_A and CCK_B antagonists on activity in the black/white exploration model of anxiety in mice.

Physiol. Behav. 54: 689-693 (1993)

HILAKIVI, L.A.; Lister, R.G.; Durcan, M.J.

Behavioral, hormonal and neurochemical characteristics of aggressive α -mice.

Brain Res. 502: 158-166 (1989a)

HILAKIVI, L.A.; Ota, M.; Lister, R.G.

Effect of isolation on brain monoamines and the behavior of mice in tests of exploration, locomotion, anxiety and behavioral despair.

Pharmacol. Biochem. Behav. 33: 371-374 (1989b)

HILAKIVI-CLARKE, L.A.; Lister, R.G.

Are there preexisting behavioral characteristics that predict the dominant status of male NIH Swiss mice (*Mus musculus*)?

J. Comp. Psychol. 106: 184-189 (1992)

HILAKIVI-CLARKE, L.A.; Turkka, J.; Lister, R.G.; Linnoila, M.

Effects of early postnatal handling on brain beta-adrenoceptors and behavior in tests related to stress.

Brain Res. 542 (2): 286-292 (1991)

HILL, D.R.; Shaw, T.M.; Graham, W.; Woodruff, G.N.

Autoradiographical detection of cholecystokinin-A receptors in brain using ¹²⁵I-Bolton-Hunter CCK-8 and ³H-MK-329.

J. Neurosci. 10: 1070-1081 (1990)

HILL, D.R.; Singh, L.; Boden, P.; Pinnock, R.; Woodruff, G.N.; Hughes, J.

Detection of CCK receptor subtypes in mammalian brain using highly selective non-peptide antagonist.

In: *Multiple Cholecystokinin Receptors in the CNS*, Dourish C.T., Cooper S.J., Iversen S.D., Iversen L.L. (Eds.), Oxford University Press, Oxford: 57 (1992)

HÖKFELT, T.; Herrera-Marschitz, M.; Seroogy, K.; Ju, G.; Staines, W.A.; Holets, V.; Schalling, M.; Ungerstedt, U.; Post, C.; Rehfeld, J.F.; Frey, P.; Fischer, J.; Dockray, G.; Hamaoka, T.; Walsh, J.H.; Goldstein, M.

Immunohistochemical studies on cholecystokinin (CCK)-immunoreactive neurons in the rat using sequence specific antisera and with special reference to the caudate nucleus and primary sensory neurons.

J. Chem. Neuroanat. 1: 11-52 (1988)

HÖKFELT, T.; Rehfeld, J.F.; Skirboll, L.; Ivemark, B.; Goldstein, M.; Markey, K.

Evidence for co-existence of dopamine and CCK in mesolimbic neurons.

Nature 285: 476-478 (1980b)

HÖKFELT, T.; Skirboll, L.; Rehfeld, J.F.; Goldstein, M.; Markey, O.; Dann, O.

A sub-population of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide - evidence from immunohistochemistry combined with retrograde tracing.

Neuroscience 5: 2093 (1980)

HOGG, S.

A review of the validity and variability of the elevated-plus-maze as an animal model of anxiety.

Pharmacol. Biochem. Behav. 54 (1): 21-30 (1996)

HOLM, M.

Prescription of benzodiazepines in general practice in the county of Arhus, Denmark.
Dan. Med. Bull. 35 (5): 455-499 (1988)

HOLMES, A.; Rodgers, R.J.

Factor analysis of behavioral responses of mice to repeated testing in the plus maze.
J. Psychopharmacol. 10 (Suppl.): A47- (1996)

HOLMQUIST, A.L.; Dockray, G.J.; Rosenquist, G.L.; Walsh, J.H.

Immunochemical characterisation of cholecystokinin-like peptides in lamprey gut and brain.
Gen. Comp. Endocrinol. 37 (4): 474-481 (1979)

HOMMER, D.W.; Stoner, G.; Crawley, J.N.; Paul, S.M.; Skirboll, L.R.

Cholecystokinin-Dopamine co-existence: electrophysiological actions corresponding to Cholecystokinin-receptor subtype.
J. Neurosci. 6 (10): 3039-3043 (1986)

HOMMER, D.W.; Skirboll, L.R.

Cholecystokinin-like peptides potentiate apomorphine-induced inhibition of dopamin neurons.
Eur. J. Pharmacol. 91: 151-152 (1983)

HONDA, T.; Wada, E.; Battey, J.F.; Wank, S.A.

Differential gene expression of CCK_A and CCK_B receptors in the rat brain.
Mol. Cell. Neurosci. 4: 143-154 (1993)

HOYER, D.

Agonists and antagonists at 5-HT receptor subtypes.
In: Serotonin, CNS Receptors and Brain Function. Bradley P.B., Handley S.L., Cooper S.J. (Eds.); Pergamon, Oxford: 29-47 (1992)

HUANG, S.C.; Fortune, K.P.; Wank, S.A.; Kopin, A.S.; Gardner, J.D.

Multiple affinity states of different cholecystokinin receptors.
J. Biol. Chem. 269: 26121-26126 (1995)

HRUBY, V.J.; Fang, S.; Knapp, R.; Kazmierski, W.; Lui, G.K.; Ymamura, H.I.

Cholecystokinin analogues with extraordinary affinity and selectivity for brain versus peripheral membrane receptors.
In: Peptides: Chemistry, Structure and Biology; Rivier J.E., Marshall G.R. (Eds.); Leiden, Holland, Escom: 53-59 (1990)

HSIAO, S.; Katsuura, G.; Itho, S.

Cholecystokinin-tetrapeptide, proglumide and open-field behaviour in rats.
Life Sci. 34: 2165-2168 (1984)

HUGHES, J.; Boden, P.; Costall, B.; Domeney, A.; Kelly, E.; Horwell, D.C.; Hunter, J.C.; Pinnock, R.D.; Woodruff, G.N.

Development of a class of selective cholecystokinin type-B receptor antagonists having potent anxiolytic activity.
Proc. Natl. Acad. Sci. USA 87: 6728-6732 (1990)

HUSTON, J.P.; Holzhäuer, M.S.

Behavioral and electrophysiological effects of intracranially applied neuropeptides with special attention to DC slow potential changes.
Ann. N.Y. Acad. Sci. 525: 375-390 (1988)

HUTSON, P.H.; Sarna, G.S.; O'Connell, M.T.; Curzon, G.

Hippocampal 5-HT synthesis and release in vivo is decreased by infusion of 8-OH-DPAT into the nucleus raphe dorsalis.
Neurosci. Lett. 100: 276-280 (1989)

INNIS, R.B.; Schneider, B.; Snyder, S.H.

Cholecystokinin-octapeptide-like immunoreactivity: histochemical localisation in rat brain.
Proc. Natl. Acad. Sci. USA 76: 521-525 (1979)

INNIS, R.B.; Snyder, S.H.

Cholecystokinin receptor binding in brain and pancreas: regulation of pancreatic binding by cyclic and acyclic guanine nucleotides.

Eur. J. Pharmacol. 65: 123 (1980)

IPP, E.; Dobbs, R.E.; Arimura, A.; Vale, W.; Harris, V.; Unger, R.H.

Release of immunoreactive somatostatin from the pancreas in response to glucose, amino acids, pancreozymin-cholecystokinin and tolbutamid.

J. Clin. Invest. 60: 760-765 (1977)

ISHIBASHI, S.; Omura, Y.; Okajima, T.; Shibata, S.

Cholecystokinin, motilin and secretin effects on the central nervous system.

Physiol. Behav. 23: 401-403 (1979)

ITHO, S.; Takashima, A.

Effect of CCK-8 antagonists on the extinction of an active avoidance task in the rat.

Drug Dev. Res. 10: 171-175 (1987)

IVERSEN, S.D.

5-HT and anxiety.

Neuropharmacology 23: 1553-1560 (1984)

IVY, A.C.; Oldberg, E.

A hormone mechanism for gall bladder contraction and evacuation.

Am. J. Physiol. 86: 599-613 (1928)

JACKSON, A.; Tattersall, D.; Bentley, G.; Rycroft, W.; Bourson, A.; Horbgreaves, R.; Tricklebank, M.; Iverson, S.

An investigation into the discriminative stimulus and reinforcing properties of the CCK_B receptor antagonist L365.260 in rats.

Neuropeptides 26: 343-353 (1994)

JAFFE, D.B.; Aitken, P.G.; Nadler, J.V.

The effects of cholecystokinin and cholecystokinin-antagonists on synaptic function in the C_{A1} region of the rat hippocampal slice.

Brain Res. 415: 197-203 (1987)

JANOWSKA, E.; Pucilowski, O.; Kostowski, W.

Chronic oral treatment with diltiazem or verapamil decreases isolation induced activity impairment in elevated-plus-maze.

Behav. Brain Res. 43: 155-158 (1991)

JEFTINA, S.; Miletic, V.; Randic, M.

Cholecystokinin-octapeptide excites dorsal horn neurons both in vivo and in vitro.

Brain Res. 213: 231-236 (1981)

JENCK, F.; Martin, J.R.; Moreau, J.L.

Behavioral effects of CCK_B receptor ligands in a validated simulation of panic anxiety in rats.

European Neuro-Psychopharmacology 6: 291-298 (1996)

JENSEN, R.T.; Lemp, G.F.; Gardener, J.D.

Interaction of cholecystokinin with specific membrane receptors on pancreatic acinae cells.

Proc. Natl. Acad. Sci. USA 77: 2079-2083 (1980)

JOHNSEN, A.H.; Rehfeld, J.F.

Cionin: a disulfotyrosyl hybrid of cholecystokinin and gastrin from the neural ganglion of the protochordate *Ciona intestinalis*.

J. Biol. Chem. 265: 3054-3058 (1990)

JOHNSON, D.N.

Effect of diazepam on food consumption in rats.

Psychopharmacology 56: 111-112 (1978)

JOHNSON, N.J.T.; Rodgers, R.J.

Ethological analysis of cholecystokinin (CCK_A and CCK_B) receptor ligands in the elevated-plus-maze test of anxiety in mice.

Psychopharmacology 124: 355-364 (1996)

JOHNSTON, A.L.; File, S.E.

Sex differences in animal test of anxiety.

Physiol. Behav. 49 (2): 245-250 (1991)

JONES, G.H.; Cole, B.J.

Are drug effects in the elevated-plus-maze dependent on the baseline level of fear?

Behav. Pharmacol. 5: 87 (1994)

JORDAN, A.D.; Kordik, C.P.; Reitz, A.B.; Sanfilippo, P.J.

Novel anxiolytic agents – 1994 to present.

Expert Opinion on Therapeutic Patents 6 (10): 1047-1060 (1996)

JORPES, J.E.; Mutt, V.

Cholecystokinin and pancreozymin, one single hormone?

Acta Physiol. Scand. 66: 196 (1966)

JORNvall, H.; Mutt, V.; Persson, M.

Structural similarities among gastrointestinal hormones and related active peptides.

Hoppe Seylers. Z. Physiol. Chem. 363: 475-483 (1982)

JOSSELYN, S.A.; Vaccarino, F.J.

Blockade of CCK_B receptors potentiates responding for conditioned rewards.

Soc. Neurosci. Abst. 20: 380 (1994)

JOYNER, K.; Smith, G.P.; Gibbs, J.

Abdominal vagotomy decreases the satiating potency of CCK-8 in sham and real feeding.

Am. J. Physiol. 264: R912-R916 (1993)

KÁDÁR, T.; Fekete, M.; Telegdy, G.

Modulation of passive avoidance behaviour of rats by intracerebroventricular administration of cholecystokinin-octapeptide sulfate-ester and nonsulfated Cholecystokinin-octapeptide.

Acta Physiol. Acad. Sci. Hung. 58 (4): 269-274 (1981)

KANFER, F.H.

The limitations of animal models in understanding anxiety.

In: Anxiety and Anxiety Disorders. Tuma A.H., Maser J.D. (Eds.); Erlbaum, Hillsdale, NJ: 245-259 (1985)

KASTIN, A.J.; Wade, L.A.; Coy, D.H.; Schally, A.V.; Olson, R.D.

Peptides and the blood-brain barrier.

In: Brain and Pituitary Peptides: 71. Wuttke A., Weindl A., Voigt K.H., Dries R.R. (Eds.); Munich, Basel, Karger (1980)

KELLOGG, C.K.; Primus, R.J.; Bitran, D.

Sexually-dimorphic influence of prenatal exposure to diazepam on behavioral responses to environmental challenge and on gamma-aminobutyric acid (GABA)-stimulated chloride uptake in the brain.

J. Pharmacol. Exp. Ther. 256: 259-265 (1991)

KEHNE, J.H.; McCloskey, T.C.; Baron, B.M.; Chi, E.M.; Harrison, B.L.; Whitten, J.P.; Palfreyman, M.G.

NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalisations.

Eur. J. Pharmacol. 193: 283 (1991)

KELLAND, M.D.; Zhang, J.; Chiodo, L.A.; Freeman, A.S.

Receptor selectivity of Cholecystokinin effects of mesoaccumbens dopamin neurons.

Synapse 8: 137-143 (1991)

KENNETT, G.A.; Curzon, G.

Evidence that mCPP may have behavioral effects mediated by 5-HT_{1C} receptors.

Br. J. Pharmacol. 94: 137-147 (1988a)

KENNETT, G.A.; Curzon, G.

Evidence that hypophagia induced by mCPP and TFMPP requires 5-HT_{1C} and 5-HT_{1B} receptors; hypophagia induced by RU24969 only requires 5-HT_{1B} receptors.

Psychopharmacol. 96: 93-100 (1988b)

KENNETT, G.A.; Whitton, P.; Shah, K.; Curzon, G.

Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT_{1C} receptor antagonists.

Eur. J. Pharmacol. 164: 445-454 (1989)

KRAMER, M.S.; Cutler, N.R.; Ballenger, J.C.; Patterson, W.M.; Mendels, J.; Chenault, A.; Shrivastava, R.; Matzura-Wolfe, D.; Lines, C.; Reines, S.

A placebo controlled trial of L365.260, a CCK-B antagonist, in panic disorder.

Biol. Psychiatry 37: 462-466 (1995)

KILLCROSS, S.; Robbins, T.W.; Everitt, B.J.

Different types of fear conditioned behaviour mediated by separate nuclei within the amygdala.

Nature 388: 377-380 (1997)

KOOB, G.F.; Heinrichs, S.C.; Pich, E.M.; Menzaghi, F.; Baldwin, H.A.; Miczek, K.; Britton, K.T.

The role of corticotropin-releasing-factor in behavioral responses to stress.

Ciba Foundation Symposia 172: 277 (1993)

KOSTOWSKI, W.; Platznik, A.; Stefanski, R.

Intrahippocampal buspirone in animal models of anxiety.

Europ. J. Pharmac. 168: 393-396 (1989)

KOSZYCKI, D.; Cox, B.J.; Bradwejn, J.

Anxiety sensitivity and response to cholecystokinin-tetrapeptide in healthy volunteers.

Am. J. Psychiatry 150: 1881 (1993)

KUMAR, R.; Stolerman, I.P.; Steinberg, H.

Psychopharmacology.

Ann. Rev. Psychol. 21: 596-628 (1970)

LAL, H.; Emmett-Oglesby, M.W.

Behavioral analogues of anxiety animal models.

Neuropharmacology 22 (12B): 1423-1441 (1983)

LAMBERTY, Y.; Gower, A.J.

Age-related changes in spontaneous behavior and learning in NMRI mice from maturity to middle age.

Physiol. Behav. 47: 1137-1144 (1990)

LARSSON, L.I.; Rehfeld, J.F.

Localisation and molecular heterogeneity of cholecystokinin in the central and peripheral nervous system.

Brain Res. 165: 201-218 (1979)

LARSSON, L.I.; Rehfeld, J.F.

Evidence for a common evolutionary origin of gastrin and cholecystokinin.

Nature 269: 335-338 (1977)

LEE, C.; Rodgers, R.J.

Antinociceptive effects of plus-maze exposure: influence of opiate receptor manipulations.

Psychopharmacology 102: 507-513 (1990)

LEVIN, A.P.; Liebowitz, M.R.

Biological factors in the description and separation of the anxiety syndromes.

In: Handbook of Anxiety. Roth M., Noyes R., Burrows G.D. (Eds.); Elsevier, Amsterdam: 157-192 (1988)

LIN, C.W.; Miller, T.R.

Both CCK_A and CCK_B/gastrin receptors are present on rabbit vagus nerve.

Am. J. Physiol. 263: R591-R595 (1992)

LINDEFORS, N.; Lindén, A.; Brené, S.; Sedvall, G.; Persson, H.

CCK peptides and mRNA in the human brain.

Prog. Neurobiol. 40: 671-690 (1993)

LINES, C.; Challenor, J.; Traub, M.

Cholecystokinin and anxiety in normal volunteers - an investigation of the anxiogenic properties of pentagastrin and reversal by cholecystokinin receptor subtype-B antagonist L365260.

Br. J. Clin. Pharmacol. 39: 235 (1995)

LISTER, R.G.

The use of a plus-maze to measure anxiety in the mouse.

Psychopharmacology 92: 180-185 (1987a)

LISTER, R.G.

The effects of repeated doses of ethanol in a hole board test.

Psychopharmacology 92: 78-83 (1987c)

LISTER, R.G.

Ethologically-based animal models of anxiety disorders.

Pharmacol. Ther. 46: 321-340 (1990)

LORÉN, I.; Alumet, J.; Hakanson, R.; Sundler, F.

Distribution of gastrin and CCK-like peptides in rat brain. An immunohistochemical study.

Histochemistry 59: 249-257 (1979)

LORZ, A.

Tierschutzgesetz mit Rechtsverordnungen und europäischen Übereinkommen.

Kommentar, 3. völlig neubearbeitete und erweiterte Auflage, C.H. Beck'sche Verlagsbuchhandlung München (1987)

LOSTRA, F.; Vanderhaeghen, J.J.

Distribution of immunoreactive cholecystokinin in the human hippocampus.

Peptides 8: 911-920 (1987)

LOTTI, V.J.; Chang, R.S.L.

A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK_B) ligand: L365,260.

European Journal of Pharmacology 162: 273-280 (1989)

LOTTI, V.J.; Pedelton, R.G.; Gould, R.J.; Hanson, H.M.; Chang, R.S.L.; Clineschmidt, B.V.

In vivo pharmacology of L364,718, a new potent nonpeptide peripheral cholecystokinin-antagonist.

J. Pharmacol. Exp. Ther. 241: 103-109 (1987)

LYDIARD, R.B.; Ballenger, J.C.; Laraia, M.T.; Fossey, M.D.; Beinfeld, M.C.

CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects.

Am. J. Psychiatry 49 (5): 691-693 (1992)

MAEDA, H.; Maki, S.; Uchimura, H.

Fascilatory effects of caerulein on hypothalamic defensive attack in cats.

Brain Res. 459: 351-355 (1988)

MAIDMENT, N.T.; Siddal, B.J.; Rudolph, V.R.; Erdelyi, E.; Evans, C.J.

Dual determination of extracellular cholecystokinin and neurotensin fragments in rat forebrain: microdialysis combined with a sequential multiple agent radioimmunoassay.

Neuroscience 45: 81-83 (1991)

MANGIAFICO, V.; Cassetti, G.; Ferrari, F.

Effect of putative anxiolytics and anxiogenics on a modified x-maze apparatus.

Pharmacol. Res. 21: 469-470 (1989)

MAKOVEC, F.; Bani, M.; Chiste, R.; Revel, L.; Rovati, L.C.; Rovati, L.A.

Differentiation of central and peripheral cholecystokinin receptors by new glutamic acid-derivates with cholecystokinin-antagonistic activity.

Drug Res. 36 (1): 98 (1986)

MALESCI, A.; Straus, E.; Yalow, R.S.

Cholecystokinin-converting enzymes in brain.

Proc. Natl. Acad. Sci. USA 77: 597-599 (1980)

MALLIEUX, P.; Vanderhaeghen, J.-J.

Cholecystokinin receptors of A type in human dorsal medulla oblongata and meningiomas, and of B type in small cell lung carcinomas.

Neurosci. Lett. 117: 243-247 (1990)

MÄNNISTÖ, P.T.; Lang, A.; Harro, J.; Peuranen, E.; Bradwejn, J.; Vasar, E.

Opposite effects mediated CCK_A and CCK_B receptors in behavioral and hormonal studies in rats.

Naunyn-Schmiedeberg's Arch. Pharmacol. 349: 478-484 (1994)

MARKS, I.M.

Fears, phobias and rituals.

Oxford University Press, New York, (1987)

MARKS, I.M.; Nesse, R.M.

Fear and fitness: an evolutionary analysis of anxiety disorders.

Ethology and Sociobiology 15: 247-261 (1994)

MARLEY, P.D.; Rehfeld, J.F.; Emson, P.C.

Distribution and chromatographic characterization of gastrin and cholecystokinin in the rat central nervous system.

J. Neurochem. 42: 1523 (1984)

MARTINEZ, J.; Rodriguez, M.; Lignon, M.F.; Galas, M.C.

Selective cholecystokinin receptor antagonists.

In: Cholecystokinin Antagonists. Wang R.Y., Schoenfeld R. (Eds.); Alan R. Liss Inc.: 29-51 (1988)

MATON, P.N.; Selden, A.C.; Chadwick, V.S.

Large and small forms of cholecystokinin in human plasma: measurement using high pressure liquid chromatography and radioimmunoassay.

Regul. Pept. 4: 251-260 (1982)

MATTO, V.; Harro, J.; Allikmets, L.

The effects of cholecystokinin A and B receptor antagonists, devazepide and L365.260, on citalopram-induced decrease of exploratory behavior in rat.

J. Physiol. Pharmacol. 47: 661-669 (1996)

MEERT, T.F.; Jannssen, P.A.J.

Psychopharmacology of ritanserin: comparison with chlordiazepoxide.

Drug. Dev. Res. 18: 119-144 (1989)

MELCHIOR, C.L.; Ritzmann, R.F.

Pregnenolone und pregnenolone-sulfate, alone and with ethanol, in mice on the plus-maze.

Pharmacol. Biochem. Behav. 48: 893 (1994)

MERLO-PICH, E.; Samanin, R.

A two-compartment exploratory model to study anxiolytic/anxiogenic effects of drugs in the rat.

Pharmacol. Res. 21: 595-602 (1989)

MERCER, L.D.; Beart, P.M.; Horne, M.K.; Finkelstein, D.I.; Carrive, P.; Paxinos, G.

On the distribution of cholecystokinin-B receptors in monkey brain.

Brain Research 738: 313-318 (1996)

MERCER, J.G.; Lawrence, C.B.

Selectivity of cholecystokinin (CCK) receptor antagonists, MK-329 und L-325.260, for axonally-transported CCK binding sites on the rat vagus nerve.

Neurosci. Lett. 137: 229-231 (1992)

MEZEY, E.; Reisine, T.D.; Skirboll, L.; Beinfeld, M.; Kiss, J.Z.

Cholecystokinin in the medial parvocellular subdivision of the paraventricular nucleus - co-existence with corticotropin-releasing hormone.

Ann. N.Y. Acad. Sci. 448: 152 (1985)

MIYAMOTO, M.; Kiyota, Y.; Nishiyama, M.; Nagaoka, A.

Senescence-accelerated mouse (SAM): age-related reduced anxiety-like behavior in the SAM-P/8 strain.

Physiol. Behav. 51: 979-985 (1992)

MICZEK, K.A.; Weertz, E.M.; Vivian, J.A.; Barros, H.M.

Aggression, anxiety and vocalization in animals: GABA-A und 5-HT anxiolytics.
Psychopharmacol. 121: 38-56 (1995)

MONTGOMERY, K.C.

The relation between fear induced by novel stimulation and exploratory behaviour.
J. Comp. Physiol. Psychol. 48: 254-260 (1955)

MORAN, T.H.; Robinson, P.H.; Goldrich, M.S.; McHugh, P.R.

Two brain cholecystokinin receptors: implications for behavioral actions.
Brain Res. 362: 175-179 (1986)

MORATO, S.; Castrechini, P.

Effects of floor surface and environmental illumination on exploratory activity in the elevated-plus-maze.
Brazilian J. Med. Biol. Res. 22: 707-710 (1989)

MORLEY, J.E.

Behavioral effects of peripherally administered cholecystokinin.
In: ISI Atlas of Science: Pharmacology 1: 49-51 (1987)

MOROJI, T.; Hagino, Y.

A behavioral pharmacological study on CCK-8 related peptides in mice.
Neuropeptides 349: 273 (1986)

MOSER, P.C.

An evaluation of the plus-maze test using the novel anxiolytic buspirone.
Psychopharmacology 99: 48-53 (1989)

MUELLER, E.A.; Murphy, D.L.; Sunderland, T.

Neuroendocrine effects of m-chlorophenylpiperazine, a serotonin agonist, in humans.
J. Clin. Endocrin. Metab. 61: 1179-1184 (1985)

MULLER, J.E.; Straus, E.; Yalow, R.S.

Cholecystokinin and COOH-terminal octapeptide in pig brain.
Proc. Natl. Acad. Sci. USA 74: 3035-3037 (1977)

MUTT, V.

Cholecystokinin: isolation, structure and function.
In: Gastrointestinal hormones. Glass G.B.J. (Ed.); Raven press, New York: 169-203 (1980)

NAJDOVSKI, T.; De Pont, J.J.H.H.M.; Tesser, G.I.; Penke, B.; Martinez, J.; Deschodt-Lanckman, M.

Degradation of cholecystokinin-octapeptide by the neutral endopeptidase EC3.4.24.11. and design of proteolysis-resistant analogues of the peptide.
Neurochem. Int. 10: 459-465 (1987)

NIEBER, K.; Henklein, P.; Ott, T.; Oehme, P.

Cholecystokinin-Peptide - neue Erkenntnisse und klinische Einsatzmöglichkeiten.
Zeitschrift für die gesamte Inn. Med. und ihre Grenzgebiete 18: 501-506 (1987)

NIEHOFF, D.L.

Quantitative autoradiographic localisation of cholecystokinin receptors in rat and guinea pig brain using ³I-Bolton-Hunter-CCK8.
Peptides 10: 265-274 (1989)

NIH

Treatment of panic disorder.
NIH Consensus Statement Online 2: 1-24 (1991)

NISHIKAWA, T.; Scatton, B.

Neuroanatomical site of the inhibitory influence of anxiolytic drugs on central serotonergic transmission.
Brain Res. 371: 123-132 (1986)

NJUNG'E, K.; Handley, S.L.

Evaluation of marble-burying behaviour as a model of anxiety.
Pharmacol. Biochem. Behav. 38: 63-67 (1991)

NOIROT, E.

Ultrasounds and maternal behaviour in small rodents.

Dev. Psychobiol. 5: 371-387 (1972)

NOLAN, N.A.; Parkes, M.W.

The effects of benzodiazepines on the behaviour of mice on the hole board.

Psychopharmacology 29: 277-288 (1988)

NUTT, D.J.

The pharmacology of human anxiety.

Pharmacol. Ther. 47: 233 (1990)

OVERMIER, J.B.; Patterson, J.

Animal models of human psychopathology.

In: *Animal Models of Psychiatric Disorders*. Simon P., Soubrie P., Wildlocher D. (Eds.); Karger, Basel: 1-35 (1988)

PALMOUR, R.M.; Ervin, F.R.; Bradwejn, J.; Howbert, J.J.

Anxiogenic and cardiovascular effects of CCK-4 in monkeys are blocked by the CCK_B antagonist LY262691.

Soc. Neurosci. Abstr. 17: 1602 (1991)

PARE, W.P.

The performance of WKY rats on three tests of emotional behavior.

Physiol. Behav. 51: 1051-1056 (1992)

PASSARO, E.; Debas, M.; Oldendorf, W.; Yamada, T.

Rapid appearance of intraventricularly administered neuropeptides in the peripheral circulation.

Brain Res. 241: 338-340 (1982)

PAVLASEVIC, S.; Bednar, L.; Qureshi, G.A.; Sodersten, P.

Brain cholecystokinin-tetrapeptide levels are increased in a rat model of anxiety.

Neuroreport 5: 225 (1993)

PAXINOS, G.; Watson, C.

The rat brain in stereotactic coordinates. 2nd Ed.

Academic Press, New York (1986)

PAZOS, A.; Probst, A.; Palacios, J.M.

Serotonin receptors in the human brain. III. Autoradiographic mapping of serotonin-1 receptors.

Neuroscience 27: 97 (1987)

PELAPRAT, D.; Broer, Y.; Studler, J.M.

Autoradiography of CCK receptors in the rat brain using [³] BOC[Nle28-31]-CCK-27-33 und [¹²⁵I]Bolton Hunter CCK-8. Functional significance of subregional distributions.

Neurochem. Int. 10: 495-508 (1987)

PELLIS, S.M.

Targets and tactics: the analysis of moment-to-moment decision making in animal combat.

Aggressive Behaviour 23: 107-109 (1997)

PELLOW, S.; Chopin, P.; File, S.E.; Briley, M.

Validation of open : closed arm entries in an elevated-plus-maze as a measure of anxiety in the rat.

J. Neurosci. Meth. 14: 149-167 (1985)

PELLOW, S.; File, S.E.

Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated-plus-maze: a novel test of anxiety in the rat.

Pharmacol. Biochem. Behav. 43: 471-477 (1986)

PELTO-HUIKKO, M.; Persson, H.; Schalling, M.; Hökfelt, T.

Immunohistochemical demonstration of cholecystokinin-like immunoreactivity in spermatozoa in epididymis.

Acta Physiol. Scand. 137: 465-466 (1989)

PERSSON, H.; Ericsson, A.; Schalling, M.; Rehfeld, J.F.; Hökfelt, T.

Detection of cholecystokinin in spermatogenic cells.

Acta Physiol. Scand. 134: 565-566 (1988)

PINGET, M.; Straus, E.; Yalow, R.S.

Localisation of cholecystokinin-like immunoreactivity in isolated nerve terminals.
Proc. Natl. Acad. Sci. USA 75: 6324-6326 (1978)

PINGET, M.; Straus, E.; Yalow, R.S.

Release of cholecystokinin peptides from a synaptosome-enriched fraction of rat cerebral cortex.
Life Sci. 25: 339-342 (1979)

PLAZNIK, A.; Palejko, W.; Nazar, M.; Jessa, M.

Effects of antagonists at the NMDA receptor complex in two models of anxiety.
Eur. Neuropsychopharmacol. 4: 503 (1994)

POLAK, J.M.; Bloom, S.R.; Rayford, P.L.; Pearse, A.G.E.; Buchan, A.M.J.; Thomson, J.C.

Identification of cholecystokinin-secreting cells.
Lancet II: 1016-1018 (1975)

POSCHEL, B.P.H.

A simple and specific screen for benzodiazepine-like drugs.
Psychopharmacology 19: 193-198 (1971)

POWELL, K.R.; Barrett, J.E.

Evaluation of the effects of PD134.308 (CI-988), a CCK_B antagonist, on the punished responding of squirrel monkeys.
Neuropeptides 19 (Suppl.): 75-78 (1991)

PSCHYREMBEL, W.

Klinisches Wörterbuch, 254. Auflage
Berlin, New York, De Gruyter (1982)

RAGURAM, R.; Bhide, A.Y.

Patterns of phobic neurosis: a retrospective study.
Br. J. Psychiatry 147: 557-560 (1985)

RATAUD, J.; Darche, F.; Piot, O.; Stutzmann, J.-M.; Böhme, G.A.; Blanchard, J.-C.

'Anxiolytic' effect of CCK-antagonists on plus maze behaviour in mice.
Brain Research 548: 315-317 (1991)

RAVARD, S.; Dourish, C.T.

Cholecystokinin and anxiety.
Trends. Pharmacol. Sci. 11: 271-273 (1990)

RAVARD, S.; Dourish, C.T.; Iversen, S.D.

Evidence that the anxiolytic-like effects of the CCK antagonists devazepide and L365.260 in the elevated-plus-maze paradigm in rats are mediated by CCK receptors.
Br. J. Pharmacol. 101: P576 (1991)

REHFELD, J.F.

Immunohistochemical studies on cholecystokinin. II Distribution and molecular heterogeneity in the central nervous system and small intestine of man and dog.
J. Biol. Chem. 253: 4022-4030 (1978)

REHFELD, J.F.

CCK and anxiety.
Introduction in: Multiple Cholecystokinin Receptors in the CNS. Dourish C.T., Cooper S.J., Iversen S.D., Iversen L.L. (Eds.), Oxford University Press, Oxford: 117 (1992)

REHFELD, J.F.; Hansen, H.F.

Characterisation of prepro-cholecystokinin products in the porcine cerebral cortex: evidence for different processing pathways.
J. Biol. Chem. 261: 5832 (1986)

REHFELDT, J.F.; Hansen, H.F.; Marley, P.D.; Stengaard Pedersen, K.

Molecular forms of cholecystokinin and the relationship to neuronal gastrins.
Ann. N.Y. Acad. Sci. 448: 11-13 (1985)

REHFELD, J.F.; Larsson, L.-L.

The predominating form of gastrin and cholecystokinin in the gut is a small peptide corresponding to their COOH-terminal tetrapeptide amide.

Acta Physiol. Scand. 105: 117 (1979)

REHFELD, J.F.; Goltermann, N.; Larsson, L.-J.; Emson, P.C.; Lee, C.M.

Gastrin and cholecystokinin in central and peripheral neurons.

Federation Proc. 38: 2325-2379 (1979)

REX, A.; Barth, T.; Voigt, J.P.; Domeney, A.M.; Fink, H.

Effects of cholecystokinin-tetrapeptide and sulphated cholecystokinin-octapeptide in rat models of anxiety.

Neurosci. Lett. 127: 139-142 (1994)

REX, A.; Fink, H.

Behavioural and neurochemical differences in Fischer 344 and Harlan-Wistar rats under aversive conditions.

Soc. Neurosci. Abstr. 23 (929.4): 2384 (1997)

REX, A.; Fink, H.; Marsden, C.A.

Cortical 5-HT-CCK interactions and anxiety-related behaviour of guinea-pigs: a microdialysis study.

Neurosci. Lett. 228 (2): 79-82 (1997)

REX, A.; Franck, S.; Fink, H.

The behavioural profile of different strains of rats.

Naunyn Schmiedebergs Arch. Pharmacol. 351 (Suppl.): R155 (1995)

REX, A.; Marsden, C.A.; Fink, H.

Effects of BOC-CCK-4 and 8-OH-DPAT on cortical extracellular 5-HT levels in guinea pigs on exposure to the elevated-plus-maze.

Peptides 19 (3): 519-526 (1998)

REX, A.; Sondern, U.; Voigt, J.P.; Franck, S.; Fink, H.

Strain differences in fear motivated behaviour of rats.

Pharmacology Biochemistry and Behaviour 54: 233-238 (1996)

REX, A.; Stephens, D.N.; Fink, H.

'Anxiolytic' action of diazepam and abecarnil in a modified open-field test.

Pharmacol. Biochem. Behav. 53 (4): 1005-1011 (1996)

REX, A.; Stephens, D.N.; Fink, H.

Pharmacological evaluation of a modified open-field test sensitive to anxiolytic drugs.

Journal of Pharmacology 7 (4): 338-345 (1993)

REX, A.; Voigt, J.P.; Voits, M.; Fink, H.

Pharmacological evaluation of a modified open-field test sensitive to anxiolytic drugs.

Pharmacol. Biochem. Behav. 59 (3): 677-683 (1998)

RODRIGUEZ-SINOVAS, A.; Fernández, A.G.; Goñalons, E.

L364,718 and L365.260, two CCK antagonists, have no affinity for central Benzodiazepine binding sites in chickens.

Life Sci. 59 (15): 1211-1216 (1996)

ROGAWSKI, M.A.

Cholecystokinin-octapeptide: effects on the excitability of cultured spinal neurons.

Peptides 3: 545-551 (1982)

ROBBINS, T.W.

A critique of the models available for the measurement of spontaneous motor activity.

In: Handbook of Psychopharmacology. Iversen L.L., Iversen S.D., Snyder S.H. (Eds.); Plenum Press, London, 7: 37-80 (1977)

ROBICHAUD, R.C.; Sledge, K.L.

The effects of p-chlorophenylalanine on experimentally induced conflict in the rat.

Life Sci. 8: 965-969 (1969)

ROCHE Lexikon der Medizin

Hrsg. Hoffmann-LaRoche AG und Urban & Schwarzenberg
München, Wien, Baltimore, Urban & Schwarzenberg (1984)

RODGERS, R.J.

Animal models of 'anxiety': where next?
Behav. Pharmacol. 8: 477-496 (1997)

RODGERS, R.J.; Cao, B.J.; Dalvi, A.; Holmes, A.

Animal models of anxiety: an ethological perspective.
Brazilian Journal of Medical and Biological Research 30: 289-304 (1997a)

RODGERS, R.J.; Cole, J.C.

The elevated-plus-maze: pharmacology, methodology an ethology.
In: Ethology and Psychopharmacology. Cooper S.J., Hendrie C.A. (Eds.); Wiley, Chichester 9 (1994)

RODGERS, R.J.; Cole, J.C.

Anxiety enhancement in the murine elevated-plus-maze by immediate prior exposure to social stressors.
Physiol. Behav. 53: 383-388 (1993b)

RODGERS, R.J.; Cole, J.C.; Cobain, M.R.; Daly, P.; Doran, P.; Eells, J.; Wallis, P.

Anxiogenic-like effects of fluprazine and eltoprazin in the mouse elevated plus maze: profile comparisons with 8-OH-DPAT, CGS120066B, TFMPP, and mCPP.
Behav. Pharmacol. 3: 621-624 (1992)

RODGERS, R.J.; Dalvi, A.

Anxiety, defence and the elevated-plus-maze.
Neurosci. Biobehav. Rev. 21 (6): 801-810 (1997)

RODGERS, R.J.; Johnston, J.N.

Cholecystokinin and anxiety: promises and pitfalls.
Critical Reviews in Neurobiology 9 (4): 345-369 (1996)

RODGERS, R.J.; Lee, C.; Shepherd, J.K.

Effects of diazepam on behavioral and antinociceptive responses to the elevated-plus-maze in male mice depend upon treatment regimen an prior maze experience.
Psychopharmacology (Berlin) 106: 102-110 (1992b)

RODGERS, R.J.; Shepherd, J.K.

Influence of prior maze experience on behavior and response to diazepam in the elevated-plus-maze and light/dark-tests of anxiety in mice.
Psychopharmacology (Berlin) 116: 237-242 (1993)

ROHMER, J.G.; Di Scala, G.; Sandner, G.

Behavioral analysis of the effects of benzodiazepine receptor ligands in the conditioned burying paradigm.
Behav. Brain. Res. 38: 45-54 (1990)

ROSE, C.; Camus, A.; Schwartz, J.C.

Protection by serine peptidase inhibitions of endogenous cholecystokinin released from brain slices.
Neuroscience 29: 583-594 (1989)

ROVATI, L.C.; Makovec, F.

New pentanoic acid derivates with potent CCK antagonist properties: different activity on the periphery vs. central nervous system.
In: Cholecystokinin antagonists. Wang R.V., Schoenfeld R. (Eds.); New York: Alan R. Liss, Inc.: 1-11 (1988)

ROWAN, M.J.; Anwyl, R.

Neurophysiological effects of buspirone and isapirone in the hippocampus: comparison with 5-hydroxytryptamine.
European J. Pharmacol 132: 93 (1986)

ROYCE, J.R.

On the construct validity of open-field measures.

Psychol. Bull. 84: 1098-1106 (1977)

RUSSO, A.S.; Guimaraes, F.S.; De Aguiar, J.C.; Graeff, F.G.

Role of benzodiazepin receptors located in the dorsal periaqueductal grey of rats in anxiety.

Psychopharmacology 110: 198-202 (1993)

RUSHTON, R.; Steinberg, H.; Tomkiewicz, M.

Equivalence and persistence of the effects of psychoactive drugs and past experience.

Nature 220: 885-889 (1968)

RYDER, S.W.; Straus, E.; Yalow, R.S.

Further characterisation of brain cholecystokinin-converting enzymes.

Proc. Natl. Acad. Sci. USA 77: 3669-3671 (1980)

SAITO, A.; Goldfine, I.D.; Williams, J.A.

Characterisation of receptors for cholecystokinin and related peptides in mouse cerebral cortex.

J. Neurochem. 37: 483-490 (1981)

SAITO, A.; Sankaran, H.; Goldfine, I.D.; Williams, J.A.

Cholecystokinin receptors in the brain: characterisation and distribution.

Science 208: 1155-1156 (1980)

SANGER, D.J.; Benavides, J.; Perrault, G.; Morel, E.; Cohen, C.; Joly, D.; Zivikovic, B.

Recent developments in the behavioral pharmacology of benzodiazepin-(omega) receptors- evidence for the functional significance of receptor subtypes.

Neurosci. Biobehav. Rev. 18: 355 (1994)

SANKARAN, H.; Goldfine, I.D.; Deveney, C.W.; Wong, K.Y.; Williams, J.A.

Binding of cholecystokinin into high affinity receptors on isolated rat pancreatic acini.

J. Biol. Chem. 255: 1849-1853 (1980)

SAUTER, A.; Frick, W.

Determination of cholecystokinin-tetrapeptide and cholecystokinin-octapeptide sulfate in different rat-brain regions by high pressure liquid-chromatography with electrochemical detection.

Anal. Biochem. 133: 307 (1983)

SAVASTA, M.; Palacios, J.M.; Mengod, G.

Regional distribution of the mRNA coding for the neuropeptide cholecystokinin in the human brain examined by in situ hybridisation.

Mol. Brain Res. 7: 91-104 (1990)

SAVASTA, M.; Ruberts, E.; Palacios, J.M.; Mengod, C.

The co-localisation of cholecystokinin and tyrosine hydroxylase mRNA in mesencephalic dopaminergic neurons in the rat brain examined by in situ hybridisation.

Neuroscience 29: 363-369 (1989)

SCHALLING, M.; Persson, H.; Pelto-Huikko, M.; Odum, L.; Ekman, P.; Gottlieb, C.; Hökfelt, T.; Rehfeld, J.F.

Expression and localisation of gastrin mRNA and peptide in spermatogenic cells.

J. Clin. Invest. 86 (2): 660-669 (1990)

SCHIFFMANN, S.N.; Teugels, E.; Halleux, P.; Menu, R.; Vanderhaeghen, J.J.

Cholecystokinin mRNA detection in the rat spinal cord motoneurons but not in dorsal root ganglia neurons.

Neurosci. Lett. 123: 123-126 (1991)

SCHIFFMANN, S.N.; Mailloux, P.; Przedborski, S.; Halleux, P.; Lostra, F.; Vanderhaeghen, J.-J.

Cholecystokinin distribution in the human striatum and related subcortical structures.

Neurochem. Int. 14: 167-173 (1989)

SCHNEIDER, L.H.; Gibbs, J.; Smith, G.P.

Proglumide fails to increase food intake after an ingested preload.

Peptides 7: 135-140 (1986)

- SCHULTZBERG, M.; Hökfelt, T.; Nilsson, G.; Terenius, L.; Rehfeld, J.F.; Brown, M.; Elde, R.; Goldstein, M.; Said, S.**
Distribution of peptide and catecholamine neurons in the gastrointestinal tracts of the rat and guinea pig: immunohistochemical studies using antisera to substance-P, VIP, enkephalins, somatostatin, gastrin, neurotensin and dopamin-B-hydroxylase.
Neuroscience 5: 689-744 (1980)
- SCHWARTZ, G.J.; Plata-Sala, H.; Fileman, C.R.; Langhans, W.**
Subdiaphragmatic effects of LPS and IL-1 β in rats.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 273 (3): R1193-R1198 (1997)
- SCHWEITZER, L.; Adams, G.**
The diagnosis and management of anxiety for primary care physicians.
In: Phenomenology and Treatment of Anxiety. Fann W.E., Karacan I., Porkorny A.D., Williams R.L. (Eds.); Spectrum NY: 19-42 (1979)
- SEIFERLE, E.**
Schmerz und Angst bei Tier und Mensch.
Deutsche Tierärztliche Wochenschrift 67: 332-334 (1960)
- SHEEHAN, D.V.; Ballenger, J.; Jacobson, G.**
The treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms.
Arch. Gen. Psychic. 37: 51-59 (1980)
- SHELDON, M.H.**
Exploratory behaviour: the inadequacy of activity measures.
Psycho. Sci. 11: 38 (1968)
- SHEPHERD, J.K.; Grewal, S.S.; Fletcher, A.; Bill, D.J.; Dourish, C.T.**
Behavioural and pharmacological characterisation of the "elevated-zero-maze" as an animal model of anxiety.
Psychopharmacology 116: 56-64 (1994)
- SHLIK, A.; Vasar, E.; Bradwejn, J.**
Cholecystokinin and psychiatric disorders: role in aetiology and potential of receptor antagonists in therapy.
CNS-Drugs 8 (2): 134-152 (1997)
- SHOWALTER, E.**
The female malady.
Pantheon Books, N.Y. (1985)
- SILVERMAN, M.; Bank, S.; Lendvai, S.**
The Cholecystokinin receptor antagonist L364.718 increases food consumption.
Dig. Dis. Sci. 32: 1188 (1987)
- SIMIAND, J.; Keane, P.E.; Morre, M.**
The staircase-test in mice a simple and efficient procedure for primary screening of anxiolytic agents.
Psychopharmacology 84: 48-53 (1984)
- SINGH, L.; Field, M.J.; Hughes, J.; Menzies, R.; Oles, R.J.; Vass, C.A.; Woodruff, G.N.**
The behavioral properties of CI-988, a selective Cholecystokinin-B receptor antagonist.
Br. J. Pharmacol. 104: 239 (1991)
- SINGH, L.; Lewis, A.S.; Field, M.J.; Hughes, J.; Woodruff, G.N.**
Evidence for an involvement of the brain Cholecystokinin-B receptor in anxiety.
Proc. Natl. Acad. Sci. USA 88: 1130-1133 (1991)
- SKINNER, K.; Basbaum, A.I.; Fields, H.L.**
Cholecystokinin and enkephalin in brain stem pain modulating circuits.
Neuroreport. 8 (14): 2995-2998 (1997)
- SKIRBOLL, L.; Hökfelt, T.; Rehfeld, J.; Cuello, A.C.; Dockray, G.**
Coexistence of substance P-like and cholecystokinin-like immunoreactivity in neurons of the mesencephalic periaqueductal central grey.
Neurosci. Lett. 28: 35 (1982)

- SKIRBOLL, L.; Hökfelt, T.; Dockray, G.; Rehfeld, J.; Brownstein, M.; Cuello, A.C.**
Evidence of periaquaeductal cholecystokinin-substance-P neurons projecting to the spinal cord.
J. Neurosci. 3: 1151-1158 (1983)
- SKIRBOLL, L.; Grace, A.A.; Hommer, D.W.; Rehfeld, J.F.; Goldstein, M.; Hökfelt, T.; Bunney, B.S.**
Peptide-monoamine co-existence: Studies on the actions of cholecystokinin-like peptides on the electrical activity of midbrain dopamine neurons.
Neuroscience 6: 2111-2124 (1981)
- SMITH, G.P.; Jeronie, C.; Norgren, R.**
Afferent axons in abdominal effect of cholecystokinin in rats.
Am. J. Physiol. 246: R638-R641 (1985)
- SNYDER, S.H.**
Chemie der Psyche: Drogenwirkung im Gehirn.
Spektrum der Wissenschaft Verlagsgesellschaft, Heidelberg (1990)
- SÖDERPALM, B.; Hjorth, S.; Engel, J.A.**
Effects of 5-HT_{1A} receptor antagonists and L-5-HTP in Montgommery's conflict-test.
Pharmac. Biochem. Behav. 32: 259-265 (1989)
- SOLL, A.H.; Amirian, D.A.; Park, J.; Elashoff, J.D.; Yamada, T.**
Cholecystokinin potentially releases somatostatin from canine fundic mucosal cells in short-term culture.
Am. J. Physiol. 248: G569-573 (1985)
- SOUBRIE, P.; Wlodaver, C.; Schoonhoed, L.; Simon, P.; Boissier, J.R.**
Preselection of animals in studies of anti-anxiety drugs.
Neuropharmacology 13: 719-728 (1974)
- STEARDO, L.; Knight, M.**
Products of cholecystokinin (CCK)-octapeptide proteolysis interact with central CCK-receptors.
Neurosci. Lett. 54: 319-325 (1985)
- STEENBERGEN, H.L.; Farabollini, F.; Heinsbroek, R.P.W.; van de Poll, N.E.**
Sex-dependent effects of aversive stimulation on holeboard and elevated-plus-maze behavior.
Physiol. Behav. 48: 571-576 (1990)
- STEIN, L.; Wise, C.D.; Berger, B.D.**
Antianxiety actions of benzodiazepines: decrease in activity of serotonin neurons in the punishment system.
In: The Benzodiazepines. Gaaratini S., Mussin E., Randall E.O. (Eds.); Raven Press, New York: 299-326 (1973)
- STENZEL-POORE, M.P.; Heinrichs, S.C.; Rivest, S.; Koob, G.F.; Vale, W.W.**
Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behaviour.
J. Neurosci. 14: 2579 (1994)
- STEPHENS, D.N.**
Animal models of anxiety; grounds for depression? Commentary on Rodgers, 'Animal models of anxiety: where next?'.
Behav. Pharmacol. 8: 497-501 (1997)
- STEPHENS, D.N.; Turski, L.; Hillman, M.; Turner, J.D.; Schneider, H.H.; Yamaguchi, M.**
What are the differences between abecarnil and conventional benzodiazepine anxiolytics?
Adv. Biochem. Psychopharmacol. 47: 395 (1992)
- STOUT, J.C.; Weiss, J.M.**
An animal model for measuring behavioral responses to anxiogenic and anxiolytic manipulations.
Pharmacol. Biochem. Behav. 47: 459-465 (1994)
- STRAUS, E.; Muller, J.E.; Choi, H.S.; Paronetto, F.; Yalow, R.S.**
Immunohistochemical localisation in rabbit brain of a peptide resembling the COOH-terminal octapeptide of cholecystokinin.
Proc. Natl. Acad. Sci. USA 74: 3033-3034 (1977)

TAKITA, M.; Tsuruta, T.; Oh-hash, Y.; Kato, T.

In-vivo release of cholecystokinin-like immunoreactivity in rat frontal cortex under freely moving conditions.

Neurosci. Lett. 100: 249-253 (1989)

TAN, E.S.

Transcultural aspects of anxiety.

In: *Handbook of Anxiety*. Roth M., Noyes R., Burrows, G.D. (Eds.), Elsevier, Amsterdam, 1: 305-326 (1988)

TALKAD, V.D.; Fortune, K.P.; Pollo, D.A.; Shah, G.N.; Wank, S.A.; Kopin, A.S.; Gardner, J.D.

Direct demonstration of three different states of the pancreatic cholecystokinin receptor.

Proc. Natl. Acad. Sci. USA 91: 1868-1872 (1994)

TAUKULIS, H.K.; Goggin, C.E.

Diazepam-stress interactions in the rat: effects on autoanalgesia and a plus-maze model of anxiety.

Behav. Neural Biol. 53: 205-216 (1990)

TAUKULIS, H.K.; Fillmore, M.T.; Ruggles, J.L.

Neuroleptic-induced changes in the anxiolytic and myorelaxant properties of diazepam in the rat.

Pharmacol. Biochem. Behav. 41 (1): 13-21 (1992)

TAYLOR, G.T.

Stimulus change and complexity in exploratory behaviour.

Anim. Learn. Behav. 2: 115-118 (1974)

TAYLOR, D.P.; Moon, S.L.

Buspirone and related compounds as alternative anxiolytics.

Neuropeptides 19: 15 (1991)

THIEBOT, M.H.; Soubrie, P.; Simon, P.; Boissier, J.R.

Dissociation de deux composantes du compartiment chez le rat sous l'effet de psychotropes. Application a l'etude des anxiolytiques.

Psychopharmacology 31: 77-90 (1973)

TREIT, D.

Animal models for the study of anti-anxiety agents: a review.

Neurosci. Biobehav. Rev. 9: 203 (1985)

TREIT, D.

Animal models of anxiety and anxiolytic drug action.

In: *Handbook of Depression and Anxiety*. DenBroer J.A., Sitsen J.M.A. (Eds.), Marcel Dekker, New York: 201-224 (1994)

TREIT, D.; Menard, D.; Royan, C.

Anxiogenic stimuli in the elevated-plus-maze.

Pharmac. Biochem. Behav. 44: 963-969 (1993a)

TRULLAS, R.; Skolnick, P.

Differences in fear motivated behaviors among inbred mouse strains.

Psychopharmacology 111: 323-331 (1993)

TURKELSON, C.M.; Solomon, T.E.; Ghamilton, J.A.

A cholecystokinin metabolising enzyme in rat intestine.

Peptides 11: 213-219 (1990)

TURNER, A.J.; Matsas, R.; Kenney, A.J.

Metabolism of cholecystokinin by endopeptidase-24.11.

Ann. N.Y. Acad. Sci. 448: 666-668 (1985)

TYER, P.

Classification of anxiety disorders: a critique of DSM-III.

J. Affective Disorders 11: 99-104 (1986)

VALLEBUONA, F.; Paudice, P.; Raiteri, S.

Release of cholecystokinin-like immunoreactivity in the frontal cortex of conscious rats as assessed by transcerebral microdialysis: Effects of different depolarising stimuli.
J. Neurochem. 61: 490-495 (1993)

VANDERHAEGHEN, J.J.; Singe, J.C.; Gets, W.

New peptide in the vertebrate CNS reacting with antigastrin antibodies.
Nature 257: 604-605 (1975)

VANDERHAEGHEN, J.J.; Lostra, F.; Vandesande, F.; Dierckx, K.

Co-existence of cholecystokinin and oxytocin-neurophysin in some magnocellular hypothalamo-hypophyseal neurons.
Cell Tissue Res. 221: 227-231 (1981)

VANDERHAEGHEN, J.J.; Crawley, J.N.

Neuronal cholecystokinin.
Ann. N.Y. Acad. Sci. 448: 1 (1985)

VANDERHAEGHEN, J.J.; Lotstra, F., DeMey, J.; Gilles, C.

Immunohistochemical localisation of cholecystokinin and gastrin like peptides in the brain and hypophysis of the rat.
Proc. Natl. Acad. Sci. USA 77: 1190-1194 (1980)

VANDERHAEGHEN, J.J.; Signeau, J.C.; Gepts, W.

New peptide in the vertebrate CNS reacting with antigastrin antibodies.
Nature (Lond.) 257: 604-605 (1975)

VAN MEGEN, H.J.G.M.; Westenberg, H.G.M.; Denboer, J.A.; Haigh, J.R.M.; Traub, M.

Pentagastrin induced panic attacks - enhanced sensitivity in panic disorder patients.
Psychopharmacology 114: 449 (1994)

VanMEGEN, H.J.G.M.; Westenberg, H.G.M.; Denboer, J.A.

The role of the central cholecystokinin-B receptor in panic disorder.
Acta Neuropsychiatrica 8 (4): 99-101 (1996)

VanMEGEN, H.J.G.M.; Westenberg, H.G.M.; Denboer, J.A.; Slaap, B.; Van Es-Rhadakishun, F.; Pande, A.C.

The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.
Psychopharmacology 129 (3): 243-248 (1997)

VASAR, E.; Peuranen, E.; Harro, J.; Lang, A.; Orelund, L.; Männistö, P.T.

Social isolation of rats increases the density of cholecystokinin in the frontal cortex and abolishes the anti-exploratory effect of caerulein.
Arch. Pharmacol. 348: 96-101 (1993)

VASAR, E.; Lang, A.; Harro, J.; Bourin, M.; Bradwejn, J.

Evidence for potentiation by CCK antagonists of the effect of cholecystokinin-octapeptide in the elevated-plus-maze.
Neuropharmacology 33: 729 (1994)

VERHAGE, M.; Ghijsen, W.E.J.M.; Nicholls, D.G.; Wiegant, V.M.

Characterisation of the release of cholecystokinin-8 from isolated nerve terminals and comparison with exocytosis of classical transmitters.
J. Neurochem. 56: 1394-1400 (1991)

VOGEL, J.R.; Beer, R.; Clody, D.A.

A simple and reliable conflict procedure for testing antianxiety agents.
Psychopharmacologia 21: 1-7 (1971)

VOIGT, J.P.; Huston, J.P.; Voits, M., Fink, H.

Effects of cholecystokinin octapeptide (CCK-8) on food intake in adult and aged rats under different feeding conditions.
Peptides 17 (8): 1313-1315 (1996)

VOITS, M.; Fink, H.; Gerhardt, P.; Huston, J.P.

Application of 'nose-poke habituation' validation with post-trial diazepam- and cholecystokinin-induced hypo- and hypermnesia.

J. Neurosci. Methods. 57 (1): 101-5 (1995)

VOITS, M.; Gerhard, P.; Fink, H.; Huston, J.P.

Memory enhancing effects of cholecystokinin fragments.

Neuropeptides 24 (4): 146 (1993)

VOITS, M.; Voigt, J.P.; Huston, J.P.; Fink, H.

The hypophagic effect of CCK-8s depends on the feeding conditions and differs in adult and aged rats.

Soc. Neurosci. Abstr. 22 (181.19): 457 (1996)

VOITS, M.; Voigt, J.P.; Boomgarden, M.; Henklein, P.; Fink, H.

Comparison of the satiating effect of the CCK_A receptor agonist A71378 with CCK-8s.

Peptides 17 (2): 355-357 (1996)

WAHLESTEDT, C.; Pich, E.M.; Koob, G.F.; Yee, Y.; Heilig, M.

Modulation of anxiety and neuropeptides Y-Y1 receptors by antisense oligodeoxynucleotides.

Science 259: 528 (1993)

WALSH, J.H.

Gastrointestinal hormones: cholecystokinin.

In: Physiology of the gastrointestinal tract. Johnson L.R., Christensen J., Jackson M.J., Jacobson E.D., Walsh, J.H. (Eds.); Raven Press, New York: 181-253 (1987)

WALSH, J.H.; Lamers, C.B.; Valenzuela, J.E.

Cholecystokinin octapeptide like immunoreactivity in human plasma.

Gastroenterology 82: 438-444 (1982)

WALSH, R.N.; Cummings, R.A.

The open-field test: a critical review.

Psychol. Bull. 83: 482-504 (1976)

WATKINS, L.R.; Kinscheck, I.B.; Mayer, D.J.

Potentiation of opiate analgesia and apparent reversal of morphine tolerance of proglumide.

Science 224: 395-396 (1984)

WENNOGLE, L.; Wysowskyj, H.; Steel, D.J.; Petrack, B.

Regulation of central cholecystokinin recognition sites by guanylnucleotides.

Journal of Neurochemistry 50 (3): 954-959 (1988)

WHITTON, P.; Curzon, G.

Anxiogenic-like effect of infusing 1-(3-chlorophenyl)piperazine (mCPP) into the hippocampus.

Psychopharmacology 100: 138-140 (1990)

WORLD HEALTH ORGANISATION

The ICD-10 classification of mental and behavioral disorders. Clinical descriptions and diagnostic guidelines.

World Health Organisation, Geneva: 1-36 (1992)

WILLIAMS, J.A.; Vigna, S.R.; Sakamoto, C.; Goldfine, I.D.

Brain cholecystokinin receptors. Binding characteristics, covalent cross-linking and evolutionary aspects.

Ann. N.Y. Acad. Sci. 448: 220-230 (1985)

WOODRUFF, G.N.; Hughes, J.

Cholecystokinin antagonists.

Ann. Rev. Pharmacol. Toxicol. 31: 469-501 (1991)

WRIGHT, I.K.; Upton, N.; Marsden, C.A.

Effect of potential anxiolytics on extracellular 5-HT in the ventral hippocampus observed of rats on the elevated-x-maze using in vivo microdialysis.

In: Monitoring Molecules in Neuroscience. Rollema H., Westerink B.H.C., Drijfhout W.J. (Eds.); University Centre for Pharmacy, Groningen: 208-211 (1991)

WRIGHT, I.K.; Upton, N.; Marsden, C.A.

Effect of established and putative anxiolytics on extracellular 5-HT and 5-HIAA in the ventral hippocampus of rats during behaviour on the elevated-x-maze.

Psychopharmacology 109: 338-346 (1992)

ZANGROSSI, H.jr.; File, S.E.

Behavioral consequences in animal tests of anxiety and exploration of exposure to cat odor.

Brain Res. Bull. 29: 381-388 (1992a)

ZANGROSSI, H.jr.; File, S.E.

Chlordiazepoxide reduces the generalized anxiety, but not the direct responses, of rats exposed to cat odour.

Pharmacol. Biochem. Behav. 43: 1195-1200 (1992b)

ZUTZEL, K.A.; Rose, C.; Schwartz, J.-C.

Assessment of the role of „enkephalinase“ in cholecystokinin activation.

Neuroscience 15: 149-158 (1985)

